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Objectives 
This guideline is intended for use in UK Genitourinary medicine clinics and sexual health services but is 
likely to be of relevance in all sexual health settings, including general practice and CASH services, 
where MSM seek sexual health care or where addressing the sexual health needs of MSM may have 
public health benefit. For the purposes of this document, men-who have sex-with-men (MSM) includes 
all gay, bisexual and all other males who have sex with other males and both cis and trans men.  This 
document does not provide guidance on the treatment of particular conditions where this is covered in 
other BASHH Guidelines but outlines best practice in multiple aspects of the sexual healthcare of MSM. 
Where prevention of STIs including HIV can be addressed as an integral part of clinical care, this is 
consistent with the concept of combination prevention and is included. The document is designed 
primarily to provide guidance on the direct clinical care of MSM but also makes reference to the design 
and delivery of services with the aim of supporting clinicians and commissioners in providing effective 
services. 
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Methodology 
This document was produced in accordance with the guidance set out in the CEG’s document 
‘Framework for guideline development and assessment’ published in 2010 at 
http:/www.bashh.org/guidelines and with reference to the Agree II instrument. Following the 
production of the updated framework in April 2015, the GRADE system for assessing evidence was 
adopted and the draft recommendations were regraded. 
  
Search Strategy (see also appendix 1) 
Ovid Medline 1946 to December 2014, Medline daily update, Embase 1974 to December 2014, 
Pubmed NeLH Guidelines Database, Cochrane library from 2000 to December 2014. Search language 
English only. The search for Section 3 was conducted on PubMed to December 2014. Priority was given 
to peer-reviewed papers published in scientific journals, although for many issues evidence includes 
conference abstracts listed on the Embase database. 
 
In addition, for Section 1.5: Identification of problematic recreational drug and alcohol use and Section 
7: Sexual dysfunction, searches included PsycINFO 
Methods 
Article titles and abstracts were reviewed and if relevant the full text article was obtained. Priority was 
given to randomised controlled trial and systematic review evidence, and recommendations made and 
graded on the basis of best available evidence. 
Piloting and Feedback 
The first draft of the guideline was circulated to the writing group and to a small group of relevant 
experts, third sector partners and patient representatives who were invited to comment on the whole 
document and specifically on particular sections. The revised draft was reviewed by the CEG and then 
reviewed by the BASHH patient/public panel and posted on the BASHH website for public consultation. 
The final draft was piloted before publication. 
Guideline Update 
 
The guidelines will be reviewed and revised in 5 years’ time, 2022. 
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1 Design and delivery of sexual health 
services for MSM 
1.1 Access to sexual healthcare 
1.1.1 Addressing the needs of subgroups of MSM 
The high and rising incidence of STIs (1)  and HIV (2)  observed in MSM in the UK are a significant public 
health priority and mean that in any geographical area a range of sexual health services are required.  
The needs of younger men, men from ethnic minorities, migrants, trans men and men who do not 
identify as gay or bisexual may not be met through services in Level 3 GUM Clinics alone.  Sexual dyad 
and network determinants and community and structural barriers (3) may mean that some groups of 
men experience higher rates of HIV despite evidence of lower rates of direct behavioural risk factors. A 
range of structural and social disadvantages (termed ‘syndemics’) (3, 4) –and including depression, 
substance use, violence, sexual stigma and homelessness show a clear dose-response relationship with 
risk of UAI and HIV infection in MSM (5, 6). There is limited evidence that such syndemics are 
associated with late HIV diagnosis in MSM in the UK (7). Several of the most effective prevention 
interventions (8) are deliverable by clinical services and equity of access can be addressed. The 
interaction between mental health, drug and alcohol use and sexual risk is recognised in the recent 
Public Health England framework for health and wellbeing of MSM (9) and associated action plan (10).  
 
Younger men across the world are disadvantaged in accessing services (11) and bear a 
disproportionate burden of STIs and HIV (12, 13) . Younger MSM may prefer to attend generic young 
people’s sexual health services rather than MSM specific services (7, 14). Data from Scotland shows 
that men under 25 are more likely to report UAI with 2 or more partners in the past year than men 
over 25 and data from Melbourne also suggests that teenage men are less likely to use condoms for 
receptive anal sex than older men (15, 16). Young MSM are more likely to suffer life stressors, anxiety, 
depression, suicide attempts and PTSD than their heterosexual peers (17).  
 
A UK cross sectional  study showed a higher HIV prevalence in black and lower prevalence in Asian 
MSM than in white British MSM (18) and black and minority ethnic (BME) MSM attending a London 
clinic were more likely to be diagnosed with rectal gonorrhoea than a matched group of white British 
men (19). However a large online survey showed no difference in reported rates of UAI (p=0.8) 
between any individual ethnic or migrant group (20). It is not therefore clear whether black or minority 
ethnicity in the UK confers a greater risk of HIV acquisition in MSM. Phylogenetic analysis suggests that 
the proportion of HIV infections in UK attributable to transmission between men may be 
underestimated: 1-11% of samples examined, recorded as heterosexual, were actually from within an 
MSM cluster. This proportion was higher for Black African men in whom the proportion was 1-21% 
(21). 
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 Addressing the sexual health needs of MSM in any geographical area requires a range of 
inclusive specialist services. These may include specialist MSM-identified clinics, outreach 
services and clinics attached to HIV services (1C) 
 
 In order to address the needs of younger men, ethnic minority men, men affected by social 
deprivation and men who do not identify as gay or bisexual; generic sexual health services 
including Youth Services, CASH and General Practice services, even if not explicitly identified 
as services for MSM, must be fully inclusive (1C) 
 
 Younger men (under 25 years) are more likely to need intensive risk reduction interventions 
(1B) 
 
 Black African men may be less likely to disclose sex with other men and opportunities for 
disclosure should be maximised (2C)  
 
 
1.1.2 Service levels and settings 
There are no studies comparing the effectiveness of different service models in detecting STIs in MSM, 
but there is evidence relating to models of HIV testing (22).  Clinical services that are identified as MSM 
clinics can significantly increase MSM attendances in established GUM and sexual health services (23, 
24) but are the preferred option for  only a minority of men (25).  Other services including CASH and GP 
services and may be more acceptable, particularly to younger men and BME men (26). In a UK survey 
of HIV positive men, 9.4%  reported using STI services remote from HIV care providers without 
disclosing HIV status (27). A majority of MSM surveyed were happy to discuss sexual health with 
general practitioners but many had not been asked about sexual orientation and were less likely to 
disclose sexual orientation to a health care worker than family, friends or colleagues (28). Young USA 
MSM were significantly (P<0.001) more likely to disclose sexual orientation to a female health care 
provider than a male one (29). In the USA non-disclosure of sex with other men is associated with 
being young, being black and having a low income (30). Phylogenetic data suggests that this issue may 
also apply to black African men in the UK (21). Many non-GUM sexual health services in the UK do not 
currently offer the full range of services to meet the needs of MSM (31) and HIV/STI risk assessment 
and offer of HIV testing were among the poorest areas of performance in a UK national audit of Level 2 
and 3 services (32).  
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 All sexual health services in a geographical area, including those offered by GPs, CASH and 
Young Peoples services, should offer a basic level of STI and HIV testing services for MSM  
(1C) 
 
 Specialist MSM Clinics can be used to increase MSM attendances in established services (2C) 
 
 All health services should establish clients’ sexual orientation and partner gender, using 
established (eg census) methodology at registration or during all routine consultations, in 
order to ensure that health needs are appropriately addressed (2D) 
 
1.1.3 Service design and outreach services 
Express style services are acceptable to MSM (33) and opt –out self-screening has high acceptability in 
HIV clinics (34) but it is not clear what proportion of MSM attending services are suitable for self-
screening services (35) and the approach has been questioned. Anogenital examination in 
asymptomatic clients including MSM yields few new STI diagnoses in retrospective studies (36, 37). 
Many services across the UK offer services including partial or complete STI screens, HIV testing and 
vaccination for Hepatitis A and or B in outreach settings including public sex environments, saunas (38, 
39) at one off events such as Pride events (40), or at home (41), with small but potentially important 
numbers of new infections detected in a variety of settings. There is evidence from the US that 
providing testing in sex-on-premises venues does not adversely affect client numbers (42). Offering 
point-of-care-testing (POCT) for HIV alone results in low levels of referral to mainstream services for 
other tests and vaccination (43), suggesting that the aim should be to offer comprehensive screening 




 Routine STI screening need not include examination in asymptomatic MSM (2C) 
 
 Outreach services should offer a comprehensive package of STI tests (2B) 
 
1.2 History taking 
 
The 2013 BASHH UK National Guideline on consultations requiring sexual history taking addresses the 
elements of sexual history taking required in all patients including MSM (44). The history should form a 
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comprehensive and holistic risk assessment including factors known to be associated with risk of STI 
and HIV infection, including frequency and number of condomless anal sex partners, serosorting, 
seropositioning, negotiated safety and use and understanding of antiretroviral drugs (ART) as HIV 
treatment-as-prevention (TasP) or PrEP (Section 6). Details of sexual activities conferring risk for 
enteric infections (Section 3) and Hepatitis A  including oro-anal sex (rimming) and for Hepatitis C 
(including fisting; 2.1.6) should be included. Discussion of ways of meeting partners including the use of 
the internet/geospatial social networking applications (apps) (Section 5.3), sex-on-premises or cruising 
venues may be helpful in assessing and addressing risk. Routine assessment of alcohol intake and the 
use of recreational drugs during sex, including practices such as injecting and booty-bumping (taking 
recreational drugs per rectum) (Section 1.3), problems with sexual dysfunction (Section 7.3) and 
condom use and errors (45) should be included. History based screening of exposed anatomical sites is 
significantly better than symptom based screening in detecting chlamydial and gonococcal infections in 
MSM (46), but there are no studies comparing history based screening with routine sampling from 
throat, urethra and rectum in every case. However the high proportion of symptomless infections and 
infections in single sites (Section 2.1) suggests that routine sampling of all sites may be a more 
appropriate protocol. This can help to avoid ‘tick box’ approach to listing anatomical sites of potential 
exposure disliked by some men (14) and allow history taking to be holistic and focus on other aspects 
of health and risk behaviour. A comprehensive risk assessment can be used to guide testing, 
recommended recall periods (Section 2.3.1) and the need for behaviour change interventions.. In men 
with rectal symptoms, the presence of tenesmus and constipation are significantly associated with 
infection with Lymphogranuloma venereum (47) and further detail may be required in men suspected 
of having sexually transmitted enteric infection (STEI). History taking in men with rectal symptoms is 




 History taking should include a holistic risk assessment to identify the factors known to be 
associated with risk of STI including HIV (see Section 2.3.1) (1C) 
 
 Appropriate questioning for Hepatitis C risk should be included in the sexual history of all 
MSM (2C) 
 
 In symptomatic men, review should routinely include questions relating to perianal and 
rectal symptoms (1C) 
 
 Questions on drug and alcohol use should be routine in all MSM consultations (1C) 
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1.3 Identification of problematic recreational drug and alcohol use  
 
Alcohol use is more common among adult MSM (48) and in adolescent MSM  (49, 50) than their 
heterosexual peers , although data from the 3rd National Survey of Sexual Attitudes and Lifestyles 
showed higher rates of smoking and recreational drug use but not current binge alcohol use in a 
population sample of 190 MSM compared to 5069 men who have sex exclusively with women (51). 
Attendees at sexual health clinics as a whole have high rates of excessive alcohol use which is 
associated with STI diagnosis (52). Self-reported surveys of convenience samples have consistently 
found that use of recreational drugs in the LGBT population is significantly higher than among WSW or 
heterosexual adults (53, 54), . This pattern is also replicated in MSM attending sexual health clinics 
(55). A systematic review of 23 studies found only use of methamphetamine and binge alcohol 
consumption to be significantly associated with increased sexual risk (56). Evidence in HIV positive 
MSM also associates polydrug use, but particularly the use of crystal methamphetamine with high risk 
sexual behaviour and incident STI (57, 58) . A review of 14 studies on the use of sildenafil found an 
independent association of sildenafil use in MSM with increased odds of serodiscordant UAI as well as 
increased risk of STI in MSM living with HIV (59). Use of inhaled nitrites (poppers) in isolation, without 
the use of other drugs is common; men may not regard this as recreational drug use and specific 
questioning may be required.  
 
In recent years it is more common for men to report the use of multiple substances (58, 60), including 
established ‘Club drugs’ and  a range of novel psychoactive substances (NPS) which continually emerge 
(61), and for which the effects and influence on sexual behaviour are less clearly understood. Clinicians’ 
awareness of ‘chemsex’ (using typically crystal methamphetamine, mephedrone or GHB/GBL 
specifically to facilitate or enhance sex) among a minority of MSM, particularly in Central and South 
East London but also in other major cities has increased dramatically over recent years. Qualitative and 
observational evidence suggests sex parties involving group sex and use of club drugs has contributed 
to the high rate of new HIV and Hepatitis C infections, including in a subset of Chemsex users,  
transmissions through intravenous use of crystal methamphetamine or mephedrone  (“slamming”) by 
inexperienced users or through deliberate sharing of blood injecting equipment (62).  ‘Club drug’ use 
was associated with higher rates of self-reported UAI in study of 246 MSM attending clinics in Brighton 
(63) and self-report of chemsex on routine enquiry was associated with a significantly higher risk of 
bacterial STI diagnosis (p<0.001) and with rectal STI diagnosis (p<0.001) in MSM attending two London 
clinics (64). Chemsex has also been strongly associated with outbreaks of sexually transmitted Shigella 
flexneri 3a infection among MSM (65, 66) as well as with cases of rectal LGV infection in HIV infected 
MSM (67). 
 
Specialist services report an increase in the proportion of clients seeking  help  with problem related to 
crystal methamphetamine, mephedrone or GHB/GBL (68). A qualitative study of MSM in Lambeth 
described MSM involved in chemsex using drugs solely in association with sex, often in clearly defined 
‘marathon sessions’ of up to 3 days and associated with predetermined decisions to have UAI with men 
believed to be seroconcordant but also associated with loss of control (69).High levels of function in 
other aspects of life such as employment are often maintained and men neither self-identify as drugs 
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users nor fit a stereotype of ‘drug user’. Routine enquiry regarding recreational drug use is indicated in 
all men disclosing other risk factors for STI and HIV acquisition (see Section 1.7) and there may be 
benefit in routinely assessing MSM (for example using self-completed screening tools) for problematic 
alcohol and recreational drug use. Brief interventions for problem alcohol use have been found to be 
effective in a range of primary care settings (70) including nurse-delivered brief interventions in a 
sexual health clinic (71) and are recommended in NICE guidance (72). However, a large randomised 
controlled trial in emergency departments showed no effect (73) and recent randomised controlled 
trial of 802 attendees (including 93 MSM) attending sexual health clinics found no significant difference 
in alcohol intake or condomless sex after 6 months  between a group universally screened for alcohol 
use and provided with brief advice by a trained clinician and (where indicated) referral to an alcohol 
health worker compared to a control group (74).  BASHH has provided guidance and recommendations 
on appropriate screening questions for recreational drug use (75). Although the harms associated with 
increased sexual risk in MSM using recreational drugs are of importance to sexual health clinicians, the 
direct harms of use of ‘Chemsex’ drugs, including the high risk of overdose and low threshold for 
dependence with GHB/GBL are likely to be an important and immediate risk to health.  Sexual health 
services may offer the sole opportunity for early intervention in MSM prior to presentation to 
emergency services. The Novel Psychoactive Treatment UK Network (Neptune) has published detailed 
guidance on the clinical management of acute and chronic harms of club drugs and novel psychoactive 
substances, with specific reference to GUM clinics (61) and including detailed guidance on the 
structure and content of brief interventions in clinical settings. 
Recommendations:  
 
 Binge drinking of alcohol, use of inhaled nitrites and methamphetamine should be employed 
as markers of increased STI risk in MSM (1A) 
 
 The use of other recreational drugs including mephedrone, other novel psychoactive 
substances NPS and non-prescribed sildenafil are also likely to be reliable markers of 
increased STI risk in MSM (1C) 
 
 Routine enquiry should cover the use of all drugs, including novel psychoactive substances 
(NPS) (2C) 
 
 All individuals who report the use of any injectable drug should be asked if injecting and if so 
is equipment ever shared (1C) 
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2 STI and HIV Testing in asymptomatic 
MSM 
2.1 Testing for asymptomatic STIs 
 
Introduction 
The following recommendations relate to testing for STIs in asymptomatic MSM. For management of 
clinical syndromes, the appropriate BASHH guidance should be followed.  
2.1.1 The range of tests provided 
BASHH has produced Recommendations for Testing for Sexually Transmitted infections in MSM in Level 
3 services (76), but all sexual health services should be able to meet the needs of MSM. All services 
offering STI testing should offer testing for MSM including NAAT testing for Neisseria gonorrhoeae (NG) 
and Chlamydia trachomatis (CT) from throat, urine and rectum, HIV, syphilis, hepatitis B and where 
indicated hepatitis C serology. National data from the Netherlands suggests that a majority of 
chlamydial and gonococcal infections in MSM would be missed if extragenital sites are not tested (77), 
although there is no published cost effectiveness data to compare this strategy with history-directed 
testing. Pooling of samples from pharynx, urine and rectum may be a means of reducing costs (78). It is 
desirable that hepatitis B vaccination is offered in all settings but the advantages of expanding the 




 All services offering STI testing should offer testing for MSM including NAAT testing for NG 
and CT  from throat, urine and rectum, HIV, syphilis, hepatitis B and where indicated (see 
2.1.6) hepatitis C serology (1B) 
 
2.1.2 Chlamydia and Gonorrhoea 
Chlamydia and gonorrhoea are among the most common STIs affecting MSM. Despite only 2.6% of the 
British male population reporting a same sex partner in last 5 years (1), in 2015 MSM accounted for 
70% (22,408/32,095) of gonorrhoea diagnoses (a 105% rise over 2012) and 21% (12,805/ 60,514) of 
chlamydia diagnoses among male attendees at GUM and integrated GUM/SRH clinic services in 
England (1). 
Infection may be carried at genital and extra-genital sites in asymptomatic MSM. Extra-genital testing 
of the pharynx and rectum is likely to play an important role in the control of both infections. 
Prevalence of extra-genital infections is high in UK, European, American and Australasian cohorts of 
HIV-negative and HIV-positive MSM (3-25). Whilst the risk of prevalent and incident chlamydia and 
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gonorrhoea infections is related to traditional markers of increased sexual risk and penetrative anal 
and oral sex, several non-penile intercourse practices such as rimming, fingering, fisting and sex toy use 
are also related to extra-genital infection (79-81). A substantial proportion of extra-genital infections 
(70-90% of rectal and 95-100% of pharyngeal) are asymptomatic (46, 82, 83).  Many pharyngeal 
infections are restricted to the pharynx (46, 84, 85). Pharyngeal gonorrhoea has a high incidence: 
prevalence ratio, suggesting spontaneous resolution (86, 87), in contrast to pharyngeal chlamydia, 
where a high prevalence: incidence ratio supports longer lived infection. Thus, pharyngeal chlamydia 
may play an important role in onward transmission (88). However, a recent longitudinal study did 
demonstrate spontaneous clearance of pharyngeal chlamydia in 37% MSM after a median of 10 days 
(89).  
Infection of the urethra with chlamydia and gonorrhoea is also common in MSM, and is associated with 
a history of penetrative oral and anal sex, but prevalence has been found at similar levels in men 
reporting only oro-insertive sex (90). A recent retrospective Australian study suggested oral sex to be 
significantly associated with urethral gonorrhoea infection (and primary syphilis), but urethral 
chlamydia was more strongly associated with anal sex (91). Both infections may be present in 
asymptomatic MSM, but in an Australian cohort of 4500 asymptomatic MSM, the prevalence of 
gonorrhoea in those without urethral symptoms (detected by NAAT) was only 0.04% (92).  
Asymptomatic infection of the rectum with gonorrhoea and/or chlamydia has been identified as a 
significant risk factor for HIV sero-conversion. This may be as a surrogate marker of sexual risk, or due 
to changes in local inflammation and immunity, enhancing susceptibility (93-96). Infection of the 
urethra (and possibly rectum) may increase likelihood of HIV transmission in HIV-positive MSM (97), 
although interim data from the PARTNER study showed no transmissions from men with undetectable 
HIV viral loads, despite significant rates of incident bacterial STI (98). Higher rates of gonorrhoea and 
chlamydia have been reported in HIV-positive MSM than in HIV-negative MSM (99-102). Thus, more 
frequent chlamydia and gonorrhoea tests should be considered for sexually active HIV-positive MSM. 
NAATs have been shown to be significantly more sensitive than culture in the detection of chlamydia 
and gonorrhoea, particularly in extra-genital sites (103-108). Owing to cross-reactivity with non-
gonorrhoea Neisseria species, all NAAT tests for gonorrhoea from all sites should be confirmed with 
supplementary tests to improve specificity (109-111). A positive predictive value (PPV) of 90% should 
be achieved in all cases (112, 113) . Where possible, prior to treatment, all sites positive for gonorrhoea 
on NAAT should have a culture performed to monitor antimicrobial susceptibility (112, 114).  First-void 
urine is the specimen of choice for genital sampling, but self-taken urethral meatus swabs have 
recently demonstrated equivalent sensitivity in the detection of both infections, and may be 
considered (115, 116). There is evidence to suggest that self-collected pharyngeal and rectal swabs 
perform as well as clinician-taken swabs from both sites, although published studies are not powered 
to exclude a difference in performance.  Self-taken swabs are highly acceptable to MSM (117-119).  
Cost effectiveness data are lacking for triple-site testing for gonorrhoea and chlamydia, but one 
modelling study examining the benefit of rectal screening on reducing HIV incidence alone in San 
Francisco has suggested that this a cost-saving intervention (120).  
Recommendations 
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 Testing should be performed with NAAT tests, with supplementary molecular testing for 
gonorrhoea (1B) 
 
 Detection of chlamydia and gonorrhoea should be offered to all MSM, from all sites (urethra, 
pharynx, and rectum) irrespective of HIV status or sexual history (2B) 
 
 First-void urine or clinician/patient collected meatal swabs are acceptable options in genital 
tract testing in asymptomatic MSM (2C) 
 
 Extra-genital sites should be sampled with clinician-collected or self-collected swabs (2C) 
 
 
2.1.3 Lymphogranuloma Venereum 
The diagnosis and management of Lymphogranuloma Venereum (LGV) is covered in a recent BASHH 
guideline (121).  LGV, caused by the L serovars of CT , has been described in association with MSM in 
the US since the 1970s (122). Since 2003, LGV infection in MSM has re-emerged with outbreaks in 
Western Europe (including the UK), North America, and Australia (123-127). The vast majority of cases 
identified have presented with a symptomatic procto-colitis, and typical cases have occurred in HIV-
positive men practicing higher risk sex (128, 129). There is a strong association between LGV infection 
and established or incident HIV infection and with incident hepatitis C infection (125). Chemsex 
(specifically the use of GHB), condomless anal sex and fisting are associated with LGV infection (67, 
130, 131). In the UK, the LGV outbreak started in 2003 and the prevalence of asymptomatic infections 
increased from 6% of serotypes in 2006 to 22% in 2012 (132, 133), meaning that LGV in the UK has now 
entered an endemic phase (134). 
The extent to which LGV is present in asymptomatic MSM, and whether this contributes to sustained 
cases in the UK, remains unclear. Some early European studies demonstrated a high prevalence of 
asymptomatic LGV infection in MSM (135, 136). In contrast, the largest published case finding study in 
UK MSM to date found LGV positivity to be 0.9% in rectal samples overall, of whom only 5% were 
asymptomatic, and only 0.04% from the urethra (137). Early US studies have also failed to detect LGV 
in asymptomatic cases (138, 139). However, a more recent case finding study in the UK identified 69 
(9%) LGV and 721 (91%) non-LGV CT  serovars from 713 men. In those with LGV for whom data was 
available 15/55 (27%) overall were asymptomatic (140).  
These observed differences may be due to methodological differences between studies, due to 
changes in LGV epidemiology, or secondary to changes in detection with more frequent extra-genital 
sampling in routine care. LGV testing should be performed in all MSM with proctitis, regardless of HIV 
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 Routine LGV typing of symptomatic and asymptomatic  chlamydia infection at  any site is 
recommended in HIV-positive but not in HIV-negative MSM (2C)  
 
 
2.1.4 Mycoplasma Genitalium 
A UK GUM clinic study demonstrated the prevalence of Mycoplasma genitalium infection (MG) at the 
urethra and rectum in MSM to be similar to that of chlamydia and gonorrhoea (2-6%), and in HIV-
positive MSM to be substantially higher (21%) (142) . US authors detected 27 (5.4%) positive rectal 
specimens for MG in 500 MSM, and again there was a strong association with known HIV infection 
(143). Other studies have demonstrated much lower prevalence figures (<2%), usually independent of 
risk factors (144, 145). Pharyngeal infection has not been described (145).  
MG is well described as a cause of non-gonococcal urethritis (NGU) (144). However, MSM with NGU 
have a lower prevalence of MG than heterosexual men, possibly because of a greater number of 
possible aetiologies in the former (146). In the UK MG study, urethral MG infection was strongly 
associated with dysuria and nearly all men with MG in the urethra were symptomatic (142). 
Conversely, rectal infection was largely asymptomatic, a finding reported in other studies, where no 
association with procto-colitis has been demonstrated (143, 145). Urethral to anal transmission has 
been described in MSM couples (147, 148) and the asymptomatic nature of rectal infection may 
provide a reservoir. 
A systematic review and meta-analysis has demonstrated an association of MG with HIV infection, 
although only two of 19 studies included MSM. However, few studies were prospective and thus the 
nature of the association and the direction of any putative causation remains unclear (148). It may be 
that MG infection increases susceptibility to HIV infection, or may be more prevalent as it is a surrogate 
marker of sexual risk.  
Recommendation 
 As most urethral MG is symptomatic, and most rectal MG infection asymptomatic and of 
uncertain consequence, routine testing of asymptomatic MSM for MG infection is currently 
not recommended in the UK (2C) 
 
2.1.5 Herpes Simplex Virus 
The seroprevalence of infection with herpes simplex virus (HSV) types 1 and 2 is high in HIV-negative 
MSM and higher still in HIV-positive MSM (149, 150). A bi-directional transmission synergy exists 
between HSV-2 and HIV infection. A meta-analysis of 19 prospective studies demonstrated prevalent 
HSV-2 seropositivity to be a statistically significant risk factor for HIV acquisition among men who have 
sex with men (151). However, suppression of HSV-2 viral replication with aciclovir in two randomised 
controlled trials has not demonstrated a reduction in the risk of incident HIV acquisition and 
transmission, possibly because suppression is incomplete with current antivirals (152, 153). Studies 
with higher dose antivirals are ongoing. The effect of prevalent HSV-1 infection remains unclear. 
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Type specific serology can be used to detect prevalent HSV infection in asymptomatic MSM. Western 
blot testing is not commercially available, but several commercial assays are available which show high 
sensitivity and specificity in sexually active adults (154), but positive predictive value can still be 
diminished when used as a screening tool (155). Pending further studies and the availability of future 
prevention strategies such as vaccines, the utility, cost effectiveness and acceptability of routine 
screening of asymptomatic HSV infection in MSM attending GUM clinics remains to be determined. 
Recommendations 
 It is not recommended that routine HSV serology be offered to asymptomatic MSM (2C) 
 
2.1.6 Hepatitis A, B & C 
For full details, please see the BASHH National Guideline on the Management of the Viral 
Hepatitides A, B & C 2015 (156) and the BHIVA Immunisation Guidelines 2015 (157). The rationale for 
routine testing in asymptomatic MSM is discussed briefly below 
Hepatitis A 
Evidence suggests MSM are not at greater risk for hepatitis A infection, and therefore routine 
screening or testing for susceptibility (with a view to vaccination) is not recommended (158, 159). 
However, several outbreaks amongst MSM in metropolitan areas have been recorded, including an 
outbreak in England and Northern Ireland in 2016-2017(160). Vaccination should be offered during 
such times to at-risk MSM attendees including those with multiple partners and those attending public 
sex venues (161, 162). Testing for prior exposure before vaccination has been shown to be cost 
effective (163).  
People who inject drugs and those living with HIV, hepatitis B and hepatitis C should be vaccinated in 
sexual health settings.  
Hepatitis B 
Incidence of acute hepatitis B in the UK remains low (164), but MSM represent a risk group and routine 
testing and vaccination is recommended for those at elevated risk, comprising all MSM, male and 
female sex workers, and people who inject drugs (165).  
Unless already known to be hepatitis B immune or chronically infected, asymptomatic MSM should be 
tested for previous hepatitis B exposure and vaccination initiated at first presentation. If testing 
identifies susceptible individuals, the vaccination course should be continued. Chronically infected 
individuals should be evaluated and referred to specialist care. 
Hepatitis C 
Parenteral spread accounts for the majority of prevalent cases of hepatitis C (HCV) in the UK (166). 
There has been a steadily rising incidence of acute HCV in MSM in England since 2000, largely 
associated with HIV infection (166). Associated factors include the presence of other STIs (particularly 
syphilis and LGV), traumatic anal sex, fisting, shared sex toys, group sex, sero-sorting and concomitant 
use of recreational drugs (including injected recreational drugs such as crystal methamphetamine in 
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“chem-sex” party settings) (167, 168). Whilst permucosal transmission does account for acquisition in 
HIV-positive men, data are lacking to support significant permucosal transmission in HIV-negative MSM 
(169, 170).  A prospective US cohort study demonstrated an association of incident HCV with higher 
numbers of receptive unprotected anal intercourse partners, as well as injecting drug use and HIV-
positive status. HCV incidence was 0.5 per 1000 PY in HIV-negative MSM compared to 4.2 per 1000 PY 
in HIV-positive MSM (171). In  a systematic review of 38 cross-sectional studies, the pooled HCV 
prevalence was found to be significantly higher in HIV-positive men (8.3%, 95% CI: 6.7-9.9) than in HIV-
negative men (1.5%, 95% CI 0.8-2.1). Of the 16 longitudinal studies included, the pooled HCV incidence 
was markedly higher in clinic-based (7.0 per 1000 person-years, 95% CI 4.6-9.5) than in community-
based (1.4 per 1000 person-years, 95% CI 0.7-2.1) studies, and in HIV-positive men (6.4 per 1000 
person-years, 95% CI 4.6-8.1) than in HIV-negative men (0.4 per 1000 person-years, 95% CI 0-0.9) 
(172). Cross-sectional prevalence of HCV amongst non-injecting HIV-negative MSM in the UK is <1.0% 
(173). However, MSM  eligible for PrEP appear to be a population at significantly increased risk of 
HCV:A higher baseline prevalence of Hepatitis C was observed in men eligible for PrEP at enrolment in 
the Amsterdam PrEP (AMPrEP) demonstration project;  18/375 HIV-negative participants (4.8%, 95%CI 
2.9%-7.5%) were anti-HCV and/or HCV RNA positive at enrolment; 15/18 (83%) had detectable HCV 
RNA. All HCV-positive MSM starting PrEP in this study were part of MSM-specific HCV clusters 
containing MSM with and without HIV.  (174) In the UK PROUD study,  5 of 160 (3.1%) men tested 
more than once for HCV had incident infection(175) and incident infections have been reported in 
routine clinical PrEP follow up (176).. The most cost-effective strategy for HCV testing among 
asymptomatic HIV-positive MSM is likely to be annual HCV antibody tests and 3–6 monthly testing of 
liver function (177).  
Recommendations 
 Routine HCV testing should be offered to asymptomatic HIV-negative MSM in the presence 
of additional risk factors (for example, sex associated with trauma or injury, history of 
recreational drug use, or rectal lymphogranuloma venereum) (2B) 
 
 Hepatitis C testing should be offered at least annually to men eligible for three monthly HIV 
testing (section 2.3.1) and those taking or eligible for PrEP. (2B) 
 
 HIV-positive MSM should be routinely screened for HCV at least annually, and whenever 
clinically indicated (1C) 
 
2.1.7 Syphilis 
Rates of infectious syphilis in MSM in the UK have continued to climb, with a 95% increase in cases 
from 2012 to 2015 (1) . MSM accounted for 84% (4,192/4,971) of syphilis diagnoses among male GUM 
clinic attendees in England in 2014 (1) 
A third of MSM syphilis cases are in HIV infected men. Infectious syphilis is endemic in London, 
Brighton and Manchester (178), but recent localised MSM outbreaks have been described, often linked 
to the use of geospatial social networking applications (179). Increased testing in all sexually active 
MSM may help contain the current epidemic (180).  
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Recommendations 
 All asymptomatic MSM should be tested for syphilis as part of sexual health screening (1B) 
2.2 HIV Testing 
 
Introduction 
In 2014, 3360 (55%) of the 6151 new diagnoses of HIV in the UK were made in MSM (2). Rates of late 
HIV diagnosis (a CD4 count <350 within 3 months of diagnosis) have declined since 2005 and are lower 
in MSM than in other transmission groups, although the absolute number of late diagnoses in MSM 
has declined only slightly from 1,131 in 2005 to 974 in 2014 (181). There is a significant geographical 
variation in rates of late diagnosis, with higher rates outside London. There has been a parallel increase 
in the proportion of recent infections as defined by the Recent Infection Testing Algorithm (RITA) (182).  
In 2014, 32% of MSM were diagnosed within 6 months of acquiring infection, compared with 27% in 
2012 and 23% in 2011. This finding is consistent with a high incidence of infection and suggests that a 
high proportion of undiagnosed infections are recently acquired. The proportion of recent infections 
was highest in the 15-24 year-old age group at 38% (2), consistent with the age-related vulnerabilities 
outlined in section 1.1.1 (15, 16, 183) . Mathematical modelling suggests that the majority of new HIV 
infections are likely to originate from men unaware of their status and that increased testing, linkage to 
care and early treatment could contribute to reduced HIV incidence (184). Hence there is a continued 
focus on avoiding harm to the individual from late diagnosis of HIV by encouraging and enhancing 
access to initial tests, but increasing attention to repeat testing to facilitate early diagnosis of recent 
infection for the purposes of prevention. Revised national BHIVA (185) and international WHO 
guidance (186) recommends starting ART before the CD4 count drops below 500mm3 based on the 
START study findings (187), so early diagnosis offers individual clinical benefit but also the possibility of 
treatment as prevention (TasP) (188) and potentially the use of PrEP for serodiscordant regular 
partners. 
 
In English Genitourinary medicine clinics in 2014, 87% of eligible MSM attendees were tested (2) . 
However, seven hundred MSM diagnosed HIV positive in 2013 were diagnosed on their first HIV test at 
that clinic (13) and 88% of all individuals diagnosed with HIV at English GUM clinics in 2014 had not had 
a previous test at the same clinic in the preceding 43 to 365 days (2). UK data collected in bars and on-
line in both London and Scotland (n=2409) shows that only 26.7% of men reporting higher risk UAI 
reported having had 4 or more tests in the previous 2 years (189). Public Health England has published 
a systematic evidence summary on reducing late HIV diagnosis in all patients groups (190). Improving 
rates of testing for those with indicator conditions, routine testing in general practice and in acute 
medical admissions are all likely to improve late diagnosis in MSM in areas with higher overall HIV 
prevalence. Opt-out testing is the appropriate approach for MSM in all settings (22) and is 
recommended in existing UK HIV Testing Guidelines (191) and NICE Guidance (192), both of which are 
currently being updated. In all cases, identifying MSM in general medical services and general practice 
is key to routine testing in this group (Section 1.1.2) and will be particularly important in areas with 
lower overall HIV prevalence where universal approaches are not adopted and where existing evidence 
shows rates of late diagnosis to be higher (2).  A systematic review found RCT evidence that point of 
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care testing (PoCT) and counselling in community outreach settings (not including general practice) 
increased uptake of HIV testing in MSM (22). Point of care testing  (PoCT) in community settings 
identified HIV infection in MSM at a significantly earlier stage than in GUM clinics (193) although 
whether this is attributable to the test or the setting is not clear. Significant improvements in both the 





 Opt- out testing for HIV infection should be offered to MSM in all settings (1B) 
 
 Opportunities for routine HIV testing in MSM in settings other than GUM clinics should be 
expanded (1C) 
 
 Point-of-care-testing for HIV in community settings should be available to MSM (1B) 
 
2.2.1 Motivation for and barriers to HIV testing 
NICE Guidance recommends that staff should ensure the provision of culturally competent care in HIV 
testing and that point of care testing should be routinely be offered alongside 4th generation laboratory 
tests (192). There is some evidence that MSM prefer less intrusive oral HIV testing to blood testing, but 
if a blood test is used then the waiting time for results is cited by users as being important (194). A 
conjoint analysis of factors affecting willingness to test in the US found that cost, timeliness of result 
and location (home vs clinic) were highly significantly associated with willingness to test (195).  A semi-
structured interview study in Boston, US, found that MSM prefer HIV testing in a venue that is friendly, 
culturally competent, gay-positive and allows for normalisation of STI/HIV testing (196). A UK study 
showed the importance of psychological barriers to testing.  It showed no reduction in clinic related 
barriers to testing over time and highlighted that fear of a positive test result remained the single most 
important barrier to HIV testing (197). 
 
Attendance for HIV testing is most commonly prompted by symptoms attributed by men to HIV 
infection and perceived HIV risk exposure (196, 198) . Learning of HIV infection in a partner or friends 
and peer encouragement to test are also cited as reasons to attend  whereas fear of a positive result 
and not self-assessing as ‘at risk’ are given as the main reason for not or never testing (199). Intensive 
peer counselling also increased the uptake of testing (22). Alternative community venues (200) are 
used for on-site testing including gay saunas (201), event-related outreach (40), and college-based 
testing  (202). Offering other tests (eg for STIs, alcohol or drug use) along with HIV testing may increase 
uptake in some groups of MSM (203).  
 
It is estimated that 33-67% of HIV infections in MSM are acquired from primary sexual partners (204) 
and in the UK approximately 40% of MSM are in a regular relationship at the time of diagnosis (7). A 
high proportion of young MSM interviewed in Scotland aspired to sex within relationships (205) and 
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testing within relationships was routine for a minority of men in an online survey of US HIV negative 
MSM, in which younger men and those with higher levels of trust in a partner were less likely to test 
(206). Couples HIV counselling and voluntary testing (CVCT) has been utilised in both clinical and non-
clinical settings and found to be acceptable and effective on a small scale in the US. An on line survey 
of 5,980 MSM found that 81.5% were willing to take part in CVCT (207). Of 95 couples tested in a study 
in Atlanta, 17% were serodiscordant (208).  
Recommendations 
 
 Offering HIV tests along with other tests, such as tests for STIs or drugs and alcohol services, 
may improve uptake among some groups of hard-to-reach men (2C) 
 
 Couples HIV counselling and voluntary testing (CVCT) for MSM should be provided and 
promoted (2C) 
 
2.2.2 Home sampling and testing 
Home sampling for HIV has high levels of acceptability among UK MSM, with a high proportion of users 
reporting never having tested before (41, 209, 210). A possible advantage over home testing is the 
capacity for laboratory confirmation of an initial reactive result and linkage to care. Home sampling 
may be promoted and incorporate risk assessment tools via social networking or other websites (209, 
211). Instant result HIV home testing kits were legalised in the UK in April 2014 (212) and the first 
commercially available kit gained a CE licence in April 2015 (213). Mixed methods research on self-
testing from the UK showed that amongst MSM (n=999), awareness of the test was low (55%) and that 
willingness to use was high (89%) (214).  In the US licensing studies of one kit (OraQuick/Orasure), a 
lower sensitivity was observed in studies involving unsupervised users than in studies of professionals 
or supervised users (215) . This suggests that interpretation or possibly acceptance of positive test 
results may occasionally be an issue. One mathematical modelling study using this sensitivity figure 
suggested that HIV prevalence in MSM would increase if home testing were to universally replace 
clinic-based testing (216). However, as a supplementary strategy home testing addresses some of the 
recognised barriers to testing (195) and may be utilised by high risk, hard-to-reach groups including 
MSM who are married to women (217). The use of voucher systems (218) or incentives (219) for home 
testing has been explored in the USA but the uptake appears to be relatively low. Guidance for users 




 Home sampling should be made available as an option for testing to all MSM (1C) 
 
 MSM should be made aware of the availability of instant result home testing as an option for 
HIV testing (2C) 
 
 Clinic services should have pathways in place for quick access and confirmatory testing for 
those reporting reactive results after home sampling or home testing for HIV (1D) 
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2.3 STI and HIV Testing 
2.3.1 Recall arrangements and frequency of routine STI and HIV testing 
International guidance from the USA , Australia and the UK recommends annual STI testing for  all 
sexually active MSM (221). US cost effectiveness analysis suggests that HIV diagnosis is cost saving up 
to a threshold cost of $22,909 (222) and that testing 3 monthly in high risk (annual incidence 1%) and 9 
monthly in moderate risk (annual incidence 0.1%) individuals in a test-and-treat model is cost effective 
(223). A further modelling study found that increasing testing from annually to 3-monthly in MSM is 
cost saving (224). An Australian modelling study suggested that increasing HIV testing in MSM from 1 
to 4 times per year was estimated to have the potential to reduce HIV incidence in NSW by 13.8% over 
10 years (225). Cost effectiveness analysis has been performed for syphilis testing in MSM living with 
HIV, suggesting 3 monthly screening is cost effective (226), but there is no comparable evidence with 
respect to other STIs in HIV negative MSM. A retrospective analysis of the impact of strictly applying 
(Australian) (221) testing frequency guidelines to MSM attendees at a large UK GUM clinic was 
estimated to increase MSM testing visits by 30% (227). There is currently no evidence on which to base 
a different frequency of routine testing for other STIs than the frequency of HIV testing.  
The presence of an acute STI, such as syphilis, chlamydia and gonorrhoea, is associated with increased 
HIV acquisition (228), the strongest association being with rectal infections (94, 95, 229). HIV incidence 
varied by the rate of incident syphilis, when controlled for known predictors of HIV in the iPrEx study of 
HIV PrEP (230). In a study of 301 MSM diagnosed with bacterial STI in a London clinic recalled at 3 
months for retesting, of whom 206 attended (231); 29 MSM per 100 person-years of follow up were 
diagnosed with a new STI and there were 5 new cases of HIV infection. Given the high rate of HIV 
transmissions occurring immediately after STI acquisition, and the fact that 4th generation tests for HIV 
will detect the great majority of HIV infections at 4 weeks after exposure(232), a routine test at first 
follow up appointment in cases of syphilis, gonorrhoea infection at any site and rectal or urethral 
chlamydial infection, as well as at 3 months post diagnosis will maximise the opportunity for early HIV 
diagnosis.  
Known markers of STI and HIV risk are inconsistently applied across UK clinics (233), suggesting  a lack 
of consistent evidence and guidance. International guidance on testing frequency from Australia (221) 
(234) and the USA (235) use a number of observational studies including a weighted risk assessment 
(236) to guide recommendations on more frequent testing in men at ‘high risk’ who have greater 
partner numbers or a history of recreational drugs use. BASHH Recommendations for Testing for 
Sexually Transmitted Infections in Men-who have sex-with-men 2014, derived from an expert 
consensus meeting in 2014 (76) suggest a much broader interpretation of MSM at ‘high risk’ to include 
any unprotected sexual contact (oral, genital or anal) with a new partner. CDC data also showed that 
there was no difference in HIV incidence rates in 7271 men in 21 cities between MSM identified as high 




 Annual STI testing including HIV testing should be recommended to all sexually active MSM 
(other than those with one long term mutually exclusive partner*) (1C) 
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 3 monthly STI testing including HIV should be offered to all those with: 
o UAI with partner(s) of unknown or serodiscordant HIV status over last 12 months 
(1B)  
o >10 sexual partners, over last 12 months (1B)  
o Drug use (methamphetamine, inhaled nitrites) during sex over last 6 months (1B)  
also, although the evidence base is less robust: 
o Drug use (GBL, Ketamine, other novel psychoactive substances (NPS) during sex over 
last 6 months (1C)   
o Multiple or anonymous partners since last tested (1C) 
      and possibly, consistent with existing BASHH guidance and US cost-effectiveness data: 
o Any unprotected sexual contact (oral, genital or anal) with a new partner since last 
tested (2D)  
 
 A repeat HIV test (alone, or with repeat STI testing depending on further risk) should be 
offered at follow up attendance after treatment for syphilis, gonorrhoea or rectal or urethral 
chlamydial infection (at a test-of-cure or first follow up serology appointment) (1C) and also 
at 3 monthly intervals for 1 year afterwards (2C)  
 
 Testing should form part of an integrated risk reduction strategy aimed at reducing 
behavioural risk (1A)  
 
* The definition of long term exclusive partner used is for more than 2 years, but there is no evidence 
on which to derive a threshold for reduced risk. 
2.3.2 Recall reminders 
SMS Text message reminders significantly (p<0.001) increased re-attendance for testing by Australian 
MSM (238) and increase the detection of gonorrhoea, chlamydia and latent syphilis (239). Smaller UK 
studies suggest SMS text reminders may be more effective in MSM than other risk groups (240)  but 




 SMS text reminders should be used to increase re-attendance and STI detection rates in 
MSM (1C) 
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3 The management of MSM with 
symptoms of sexually transmissible 
enteritis and proctitis 
3.1 Introduction  
 
Rectal symptoms among MSM presenting to GUM clinics are common (242, 243). Symptoms may be 
attributable to STIs acquired through anal sex (typically associated with proctitis) and/or those 
acquired through a faecal-oral route, typically causing gastroenteritis. These infections are referred to 
in this guideline as sexually transmissible enteric infections (STEI).  
Diagnoses of Shigella flexneri 3a, S. flexneri 2a and S. sonnei in men without a travel history have 
increased markedly (244)  while diagnoses in women have remained stable, strongly suggesting sexual 
transmission between MSM as the cause, and there has been a recent cluster of verotoxin-producing 
Escherichia coli 0117:H7 (VTEC) found among MSM (245). It is particularly important to identify enteric 
pathogens as the cause of symptoms in MSM, as STEIs will often require collaborative work between 
primary care and GUM/HIV clinicians, microbiologists and local health protection teams to ensure 
appropriate clinical and public health management is undertaken in a timely manner.  
For opportunistic enteric infections in HIV positive MSM, refer to British HIV Association and British 
Infection Association guidelines 2011 (246).  
3.2 Aetiology 
 
STIs causing proctitis (Table 1) are transmitted rectally through receptive anal intercourse or fomites 
(fingers, sex toys or other objects carrying these pathogens) or through oro-anal intercourse. 
Enteric pathogens, which are statutorily notifiable, tend to cause enterocolitis, although symptoms 
may overlap with those caused by STIs and there may be dual pathologies (247-250). Acquisition of 
enteric pathogens may be linked to travel or occur in outbreaks related to food in addition to person-
to-person transmission (e.g. for Norovirus). However, there is increasing evidence that a range of 
enteric infections may be transmitted during sex between men (Table 1). Faeco-oral transmission may 
be through direct oro-anal practices, indirectly through oral sex after anal sex or via fingers (either 
directly into mouth or via food) or fomites. 
 
Causes of sexually transmitted proctitis Causes of sexually transmitted enteric 
infections 
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    Genotypes D-K 
    Genotypes L1-3 (LGV*) 
Treponema pallidum 









Microsporidium spp.$  
Hepatitis A 
Table 1 Aetiological agents of sexually transmitted proctitis and enteric infections(de Vries et al., 
2013)(251)  
*Lymphogranuloma venereum 
#Verotoxigenic Escherichia coli 
$Opportunistic infections in advanced HIV positive immunosuppression 
Infectious causes of gastrointestinal infections in MSM include (252-254): 
 Viruses: Hepatitis A (see Section 2.1.6), Norovirus (In immunocompetent patients, Adenovirus 
and Rotavirus are implicated in childhood gastroenteritis only) 
 Bacteria: Campylobacter sp., Escherichia coli, Salmonella sp., Shigella sp., Yersinia enterocolitica 
(N.B. gastrointestinal infections not associated with   transmission via sexual practices in the 
UK: Vibrio cholera,; Clostridium difficile ,; Bacillus cereus) 
 Parasites: Cryptosporidium sp., Entamoeba histolytica, Giardia lamblia/intestinalis, Blastocystis 
sp., Dientamoeba fragilis, Isospora sp., Microsporidium sp. 
 
A national outbreak of S. flexneri 3a in MSM started in 2009, and there is good evidence of sustained 
transmission of S. flexneri 2a and S. sonnei  between MSM since 2010, suggesting separate 
introductions in the MSM population (244). Most MSM with S. flexneri 3a were white, UK-born, HIV-
positive, and reported high numbers of casual and regular partners, and infection was associated with 
(i) low awareness about enteric infections, (ii) chemsex, and (iii) meeting sex partners and locating sex 
parties through social and sexual networking applications (66, 244, 255, 256). Co-infections with other 
STIs and with viral hepatitides and HIV are also common (66, 248, 250, 255, 257, 258). 
Reduced sensitivity to antimicrobial agents, particularly to fluoroquinolones and macrolides (259-262) 
is a significant problem for some enteric pathogens and for STIs such as NG (263-265)and MG (145, 
266, 267). Appropriate selection of antibiotics (antibiotic stewardship) is therefore required, based 
wherever possible on antibiotic susceptibility profiles.   
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3.3 Clinical features 
MSM reporting symptoms of enteric or rectal infections usually fit into one of two presentation types, 
although mixed symptoms are not uncommon (247, 248, 250, 268-270)  
Symptoms of proctitis include rectal pain, discharge or bleeding, with or without tenesmus. The 
aetiology is usually classic STI pathogens (CT including LGV serovars, NG, T. pallidum and HSV) 
transmitted via receptive anal sex (247, 249, 250, 268, 271) Treatment of these pathogens is covered in 
the appropriate BASHH guideline. MG, though found in the rectum, is not thought to be associated 
with a proctitis syndrome (142, 143, 145, 272).  
Patients with symptoms of enteric infections including diarrhoea and/or dysentery and abdominal pain 
usually have colitis or enterocolitis that is caused by enteric pathogens, referred to in this guideline as 
sexually transmissible enteric infections (STEI). Mixed proctitis/STEI presentations and multiple 
infections are not uncommon. 
 
 
Figure 1. Classification of MSM presenting with symptoms of proctitis or STEI 
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3.4.1 Proctitis  
Symptoms of rectal pain, bleeding with fresh blood, and discharge are indicative of involvement of the 
rectum and the anal canal. See Figure 2 for assessment. 
3.4.1.1 Diagnosis: History and Examination 
The history should include a description of symptoms and duration (44, 273, 274). The sexual history 
should focus on the 4-weeks period prior to onset of symptoms (to cover the look back period for LGV 
and gonorrhoea) (275).  
A thorough genito-anal examination is required (128, 271) including examination with a proctoscope if 
tolerated (276, 277). In cases of severe proctitis, blind (i.e. without the use of the proctoscope to 
visualise the mucosa) ano-rectal swabs may be necessary. 
 
3.4.1.2 Diagnosis: Investigations 
A full sexual health screen should be offered (271, 278, 279) (Section 2.1.1). Microscopy of a Gram-
stained rectal smear should be performed and where possible culture for NG from all sites prior if 
treatment is to be given. Additional swabs for HSV PCR and T. pallidum PCR (where available) should be 
taken if ulcers are present.  
Finding of >5 (280) or >10 (136) polymorphonuclear cells (PMNC)/high power field (HPF) on 
microscopic examination of a Gram-stained rectal swab smear indicates proctitis.  
Recommendations 
 A full sexual health screen should be offered (1B)  
 
 Rectal swabs should be sent for culture and sensitivities for NG if treatment is to be given at 
presentation (1B) 
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Figure 2. Assessment of MSM presenting with symptoms of proctitis. (Also assess for enteric 
infection; see section 3.4.2 and fig.4) 
 
 
3.4.1.3 Further Investigations and Treatment 
Management is summarised in Figure 3Figure 3. CT  or LGV as an aetiology must be considered in 
addition to  other diagnoses indicated by examination findings (such as HSV or Syphilis with ulcerative 
features) (271). 
Examination and findings of microscopic examination of Gram-Stained smears from rectal swabs 
should guide therapeutic decisions and follow the relevant specific infection guideline (accessed at: 
http://www.bashh.org/BASHH/Guidelines/Guidelines/BASHH/Guidelines/Guidelines.aspx)  
If CT is detected, testing for LGV-specific DNA should be done by sending the residual NAAT specimen 
or a fresh rectal swab to the local microbiology laboratory, where available or to Public Health 
England’s Sexually Transmitted Bacteria Reference unit in England and Wales or Health Protection 
Scotland’s Scottish Bacterial Sexually Transmitted Infections Reference Laboratory in Scotland (141). 
Empirical treatment should cover LGV (121, 271) and gonorrhoea as the prevalence of NG amongst 
MSM is high and the sensitivity of microscopy examination of Gram stained rectal swabs for 
gonorrhoea is low (281). Patients with rectal STIs are at high risk for other STIs, including HIV and 
Hepatitis C and so follow up STI and HIV testing both at test-of-cure and at 3 months is recommended 
(282). 
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Figure 3. Management of MSM presenting with symptoms of proctitis (de Vries et al., 2013)(271) 
 
Recommendations  
 Rectal chlamydia, if detected, should be typed for LGV serovars in HIV positive and HIV 
negative MSM with proctitis (1B) 
 
 Examination and findings of microscopic examination of Gram-Stained smears from rectal 
swabs should guide therapeutic decisions (1B) 
 
 Empirical therapy, in symptomatic men with proctitis in whom rectal chlamydia status is 
unknown, should include LGV (which also effectively treats syphilitic proctitis) and 
gonorrhoea treatment (1B)  
 
 Offer Hepatitis C testing to all HIV positive MSM and HIV negative MSM with risk factors at 3 
months’ follow up (1D) 
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3.3.1.4 Contact tracing and treatment 
Partner notification for STIs is covered in the BASHH statement on partner notification (275).  
Recommendations  
 Active partner notification covering up to at least the 4-week period prior to symptom onset 
should be attempted and documented (1B) 
 
3.4.2 Sexually transmitted Enteric Infections (STEI) 
Enteric infections are characterized by sudden onset of diarrhoea, with or without vomiting and are 
usually transient disorders due to enteric infection with viruses, bacteria, or protozoa, typically 
affecting the large bowel (the colon) and less commonly, the small bowel. Other symptoms include 
blood and/or mucous in the faeces (dysentery), and fever or malaise. The diagnosis is usually made on 
the basis of clinical symptoms and signs. Microbiological tests of faecal samples are necessary to 
determine the causative organism. Infectious bloody diarrhoea as a clinical syndrome is a notifiable 
infection and should be notified to the Local Authority Proper Officer (Section 3.5.1) (283, 284)  
Diagnosis: History and Examination  
Assessment is summarised in Figure 4 (65, 66, 253, 254, 285, 286). History should include questions on 
the severity of illness, medication and risk factors, including travel abroad and food history (Map: 
Appendix 2.1). Sexual risks within the 2 weeks preceding onset of symptoms should be assessed 
including: receptive oro-anal sexual contact (both direct as well as indirect, i.e. performing oral sex 
after anal penetration (of another partner), multiple sexual partners and participating in group sex, 
sexual activity involving recreational drug use (chemsex – Section 1.3 ) and sexual activities involving 
faeces (e.g. scat play) 
Symptoms of diarrhoea may be mild and may not be elicited in the history without direct questioning if 
other symptoms of discomfort, pain or tenesmus predominate. 
Symptoms of STEI tend to be acute. However, with parasitic infections such as giardiasis and 
amoebiasis, chronic symptoms are not uncommon. LGV may also present as a chronic enteritis with a 
presentation not unlike inflammatory bowel disease. 
Examination should include assessment of the severity of infection, including the severity of 
dehydration (Appendix 1.2), particularly in patients who are unwell or frail (older age, advanced HIV 
infection or other co-morbidities). The presence of blood/mucous in faeces, prolonged (more than 7 
days) diarrhoea, and systemic features such as fever (especially), weight loss and dehydration, would 
be considered indicative of severe infection and hospital admission should be considered.  
Examination of the patient should include assessment for proctitis as described above (Section 3.4.1.1) 
 
RECOMMENDATIONS:  
 History should cover assessment of duration and severity of symptoms, identify potential 
causes and risk factors for complications and public health risk (1B) 
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Figure 4. Summary of salient features of clinical history in assessing MSM with enteric infections 
(Also assess for proctitis; see section 3.4.1 and fig. 2) 
 
 
3.4.2.2. Diagnosis: Investigations 
Investigations should include a full sexual health screen as described in section 3.4.1.2 
Microbiology examination of stool is recommended in all cases and is essential when the patient: 
 needs antibiotics. 
 is systemically unwell. 
 needs hospital admission. 
 has blood, mucous or pus in stool. 
 has diarrhoea after foreign travel 
 is immunosuppressed. 
 
Include examination for ova, cysts and parasites (up to 3 samples taken at 3 different occasions might 
be needed), culture with antibiotic susceptibility testing, and where available, molecular detection 
assays (such as PCR). It is important that the faecal samples are collected properly (as described in 
Appendix 2.3) and for each investigation, a minimum of 1ml of faeces is required. 
RECOMMENDATIONS:  
 Assess for severity including evidence of dehydration (1A) and fever 
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 Consider referral to tertiary care or specialist inpatient units for severe infections (1A) 
 
 Send faecal samples for microbiological examination (1A)  
 
 Offer STI and HIV testing (1B)  
 
 Assess for proctitis (1B)  
 
3.4.2.3 Further Investigations and Treatment 
The majority of patients with STEI have a brief self-limiting illness and can be managed conservatively 
(253, 287-290).  
Oral rehydration therapy, if required, consists of using oral rehydration salts taken after every loose 
stool passed for up to 48 hours (253, 289)  
Antidiarrhoeal  (or antimotility) drugs such as loperamide are contraindicated for the management of 
infectious diarrhoea (253, 289, 290) 
The use of empirical antibiotic therapy, where the diarrhoea is mild and of unknown aetiology,  is not 
recommended. Evidence suggests that they have minimal benefits, with high rates of side effects 
reported (253, 288, 291) and their use promotes the development of resistant bacteria (260, 291-293). 
Circulating Shigella sp. and other enteric infections are reported to have high prevalence of resistance 
to antibiotics, particularly macrolides and fluoroquinolones (259-262, 292, 294, 295). However, 
empirical therapy guided by microbiology advice based upon most likely aetiology, may be considered 
when: 
 The patient is pyrexial (temperature ≥38⁰C) 
 The stools are bloody 
 Diarrhoea lasts more than 7 days 
 Co-morbidities (frailty, inflammatory bowel disease, immunocompromised state e.g.  advanced 
HIV infection, immunosuppressive agents, etc) are present 
 
Where a microbiological cause is known antibiotic therapy may be appropriate. The choice of agent is 
best guided by microbiology advice informed by either antibiotic susceptibility profile of an isolate or 
from local susceptibility data. 
HIV positive patients were reported to have more recurrent, persistent and invasive infections in the 
pre-HAART era. There are a few case reports of invasive shigellosis in MSM with well controlled HIV 
infection. However, there are no data comparing clinical outcomes of STEI in well-controlled HIV 
positive MSM and MSM without HIV. 
RECOMMENDATIONS:  
 Advise on Oral rehydration therapy (1A) 
 
 Avoid antimotility agents if invasive disease or infectious agents are suspected (1A) 
 
 Consider empirical antibiotic therapy only in severe disease or in the presence of 
complicating co-morbidities (1A)  
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 Antibiotic therapy should be guided by local antimicrobial resistance patterns (1B)  
 
3.4 Preventing the spread of infection   
 
All patients with suspected or confirmed STEI should be provided with advice on the prevention of non-
sexual and sexual transmission of infection. Clinical syndromes of infectious bloody diarrhoea, 
haemolytic uraemic syndrome, and food poisoning, even of unproven aetiology, are statutorily 
notifiable (Section 3.5.3) (283, 284). 
 
3.5.1 Advice on preventing the non-sexual spread of infection (285) 
Detailed advice should be provided on the non-sexual transmission of infection. (Appendix 2.4) 
RECOMMENDATIONS:  
 Advise on hygiene (1B) 
 
 Advise to avoid return to work until 48 hours after last episode of diarrhoea (1B) 
 
 For patients who work as food handlers or with people vulnerable to infections, return to 
work should be guided by local public health authorities (Statutory requirement, Section 
3.5.3) 
 
3.5.2 Advice on sexual practices for preventing spread of infection (296)  
 Wash hands, genitals and perianal skin before and after sexual activities such as intercourse, 
rimming, fingering or handling used condoms and sex toys. If possible, showering is advised as 
bacteria like Shigella may be present on other skin surfaces. 
 Use condoms for anal sex and latex gloves for digital penetration or fisting. Dental dams or a 
condom cut into a square to make a barrier for rimming. 
 Avoid sharing sex toys or douching equipment. 
 Avoid recommencing sexual contact until 7 days after the last episode of diarrhoea. 
 
RECOMMENDATIONS:  
 Advise on hygiene practices before and after sexual contact (1B) 
 
 Advise on barrier protection and refraining from sharing toys or personal hygiene devices 
(1B) 
 
 Advise on abstinence from sexual contact for 7 days after the last episode of diarrhoea (2D) 
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3.5.3 Other public health actions 
Effective management of enteric pathogens requires notification to the Local Authority proper officers 
under the respective Health Protection (Notification) Regulations and Public Health Acts in each 
country (283). Lists of notifiable diseases and organisms and associated guidance on how to report in 
each country are available. [See Box 1] Clinical syndromes should be reported by the attending clinician 
who first saw the patient for the episode; laboratory diagnoses are, in addition, statutorily reported 
separately by laboratory personnel.  
Local health protection teams and environmental health officers will often need to contact patients to 
undertake a questionnaire to ascertain the likely source of infection and linked cases. For patients 
diagnosed with STEI it may be appropriate for the GUM clinic to assist in completing the questionnaire 
and obtaining this information , and collaborate closely with the local health protection teams (284). 
 
RECOMMENDATIONS:  
 The attending physician should report all cases, with contact details, of enteric infections, 
regardless of confirmation, to the relevant local health protection team (Statutory 
requirement)(275) 
 
3.5 Asymptomatic infections 
 
The majority (>80%) of rectal STIs are asymptomatic (297) and are a reservoir for onward transmission 
and increase the risk of HIV acquisition and transmission(298, 299). Treatment results in a  reduction in 
onward transmission of the infection (300) as well as of HIV (298). However, there are no data on 
asymptomatic carriage of enteric pathogens within cohorts of MSM.  
Box 1. Health Protection (Notification) Regulations and Public Health Acts in 
each country 
1. England works to the Health Protection (Notification) Regulations 2010 
(http://www.legislation.gov.uk/uksi/2010/659/contents/made ). The list of notifiable 
diseases and guidance on reporting in England can be accessed at: 
https://www.gov.uk/guidance/notifiable-diseases-and-causative-organisms-how-to-
report  
2. Wales works to The Health Protection (Notification) (Wales) Regulations 2010 
http://www.legislation.gov.uk/wsi/2010/1546/contents/made . The list of notifiable 
diseases and guidance on reporting in Wales can be accessed at: 
http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=48544  
3. Northern Ireland works to the Public Health Act (Northern Ireland) 1967 
(http://www.legislation.gov.uk/apni/1967/36/contents). Northern Ireland uses the 
list of notifiable diseases and used in England (see 1. above) 
4. Scotland works to the Public Health Scotland Act 2008. The full list of notifiable 
disease in Scotland can be accessed at: 
http://www.legislation.gov.uk/asp/2008/5/schedule/1 and guidance on how to 
report in Scotland can be accessed at: 
http://www.gov.scot/Topics/Health/Policy/Public-Health-
Act/Implementation/Guidance/Guidance-Part2  
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Testing and treating asymptomatic contacts of STEIs for enteric infections is not recommended at 
present. MSM with enteric infections, however, are part of a sexual network that is high risk for other 
STIs; engaging contacts of STEI with STI testing and prevention interventions is good clinical practice 
from a public health STI control perspective. 
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4 HPV infection and anal dysplasia in 
MSM 
4.1 HPV Infection 
Two issues arise with HPV infection in the ano-genital area in MSM; genital warts and epithelial 
neoplasia. HPV subtypes 6 and 11 cause genital warts; subtypes 16, 18, 31 and 33 are associated with 
neoplasia. HPV may also infect and persist in the oropharynx and may lead to oropharyngeal squamous 
cell carcinoma. Anogenital warts in MSM should be managed according to current BASHH guidelines 
(301).  
4.1.1 Anal dysplasia 
Screening for anal dysplasia in MSM using anal cytology remains controversial. Although biennial 
screening for AIN in HIV negative MSM has been suggested (302) it is not routinely practiced and cost 
effectiveness is unproven. MSM with HIV are reported to have a higher frequency of prevalent high risk 
HPV strains, persistence of HPV, incident  anal dysplasia, progression to and relapse of anal intra-
epithelial neoplasia (AIN) and anal cancer than heterosexual men and women (303, 304) . An Australian 
meta-analysis estimated an anal cancer rate of 46 per 100,000 HIV-infected MSM, with US rates 
around 135 per 100,000 (305). An evidence based UK cost effectiveness analysis in 2010 concluded 
that screening did not reach the cost effectiveness threshold (306), although an Australian study 
published in 2000 showed that 2 or 3 yearly screening in MSM was cost-effective (307).  Smoking is 
identified as a risk factor for external genital warts, anal dysplasia and anal cancer among HPV infected 
MSM (308, 309). Lower CD4 counts (<350 cells/microL) are strongly associated with prevalent high risk 
HPV strains (OR 3.65; 95% confidence interval [CI], 1.28-10.4) (309) . There are no RCTs evaluating 
impact of antiretroviral therapy (ART) on HPV or dysplasia. Some cohorts report  lower prevalence of 
HPV and anal dysplasia (310), others report no effect with ART (311).    
Despite the high rates of abnormalities reported there are no evidence-based recommendations on 
screening for anal dysplasia.   Where expertise in high resolution anoscopy exists, routine anal cytology 
may be performed (312), although the specificity of the technique in detecting high grade lesions is 
only 32% to 59% (313), meaning that a screening program is likely to be highly resource intensive.  
Retrospective studies of large scale screening programs suggest that the vast majority of anal cancers 
present with a lump and over half of anal cancers detected by digital examination are asymptomatic. 
There is limited evidence that a screening programme utilizing perianal examination and digital ano-
rectal examination (DARE) is both acceptable and depending on the base case variables used might be 
cost-effective for HIV positive MSM (314). Screening those over 50 every 2 years yielded an 
incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) of AUD 29 760 
compared with AUD 45 484 for screening 4 yearly.  
MSM Guideline Final Accepted version 021117. Note this version does not include typesetting and 
proofreading changes included in published version which is available on the BASHH website. 
 
However questions remain. Only one small, short term study on acceptability has been published 
(315). In this study 28% of those approached declined to take part. The cost-effectiveness models 
above were partly based on this study. These models were very sensitive to the costs of managing false 
positive results and to assumptions regarding sensitivity of screening and rates of progression. While 
non-Australian healthcare costs were modeled these findings were not published. The European AIDS 
clinical society guidelines recommend that digital anal examination +/- PAP smear every 1-3 years in 
MSM with HIV infection should be considered but this is an expert recommendation only (316). To-
date the recommendation has not been taken up by other guidelines. The possibility of using digital 
anal self-examination has been explored but there is insufficient evidence on which to base any 
recommendation(317). 
HPV may also affect the oropharynx where it may lead to squamous cell carcinoma. Ong et al found 
19% (33/173) of MSM with HIV had any oral HPV genotype detected; 43% of these had the same 
genotype detected 3 years later and 40% were high risk genotypes (318). This compares with a 
prevalence of 7% for any oral HPV in general population (319). HPV persisted in HIV negative MSM for 
a median of 6.9 months for any HPV genotype and 6.3 months for high risk strains (320). However, 
there is no data to suggest an increased frequency of oropharyngeal cancers in MSM and some to 
suggest that, in HIV infected MSM at least, the frequency may be lower than in heterosexual men 
when matched for partner numbers and other risk factors (321). Oral HPV testing remains a research 
tool and is not currently recommended in clinical practice.    
Recommendations 
• Genital warts in MSM should be managed according to existing BASHH guidelines (1C) 
 
• HIV units should develop either local clinical expertise or referral pathways for suspected 
anal cancer and anal dysplasia. (2C) 
 
• Regular digital ano rectal examination (DARE) can be incorporated into routine HIV care and 
may be cost effective in MSM over 50 (2B) 
 
4.2 HPV vaccination in MSM 
 
HPV vaccine is most effective when administered before the onset of sexual activity. However in the 
UK, universal HPV vaccination is only available for girls. Unvaccinated heterosexual boys benefit from 
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herd immunity but young MSM do not experience significant benefit (322) . In November 2014, the 
(UK) Joint Committee on Vaccination and Immunisation (JCVI) issued an interim position statement , 
having reviewed an unpublished impact and cost effectiveness analysis on vaccinating MSM when 
attending sexual health clinics. JCVI recommended that a programme for the vaccination of MSM aged  
45 years and younger should be implemented in GUM and HIV clinics in the UK using the quadrivalent 
HPV vaccine with a 3 dose series (0, 1-3, and 6 months or 0,6 and 12 months), subject to the 
programme being commissioned and implemented at a cost-effective price (323). Vaccination is 
available at a number of pilot sites in England and at clinics in Scotland. Dosage timings can be adjusted 
to correspond with routine sexual health or HIV clinic visits. For guidance, in a three-dose schedule, the 
second dose should be administered at least one month after the first dose and the third dose should 
be administered at least three months after the second dose. All three doses should ideally be given 
within one year; however, a 24-month period is clinically acceptable. 
4.2.1 Acquisition of HPV 
The prevalence of high risk HPV increases quickly in MSM throughout the late teens and is strongly 
associated with numbers of sexual partners. In a group of 16-20 year old MSM in Australia the 
proportion of men with anal HPV of any type increased from 10.0% in men reporting no prior receptive 
anal sex to 47.3% in men reporting ≥4 receptive anal sex partners (P < .001) A similar pattern was also 
seen with HPV type 16 (P = .044). However there is also evidence that a substantial proportion of MSM 
appear to remain uninfected with vaccine specific/targeted types into their 20s and 30s.  In a London 
study 25.1% of MSM aged between 18 and 40 had DNA evidence of one quadrivalent vaccine HPV 
types, while only 7.4% had presence of two HPV vaccine types or more. These findings offer the 
possibility that HPV vaccination may also benefit older individuals (324).  
 
4.2.2 Quadrivalent HPV (qHPV) vaccine efficacy in MSM - HIV negative 
The efficacy of qHPV vaccine was investigated in a placebo controlled trial of 4065 HIV negative males 
including 602 MSM aged 16-26 years followed for a median of 2.9 years. (325). Vaccination resulted in 
a 63.7% reduction in external genital lesions (EGL) related to vaccine HPV types in heterosexual men, 
70.2% (23.0-90.2) in MSM (ITT). The per-protocol efficacy was 90.5%.   
The efficacy of qHPV vaccine in 16 – 26 year old MSM against AIN was 50.3% (intention-to-treat) and 
77.5% (per-protocol) (326). Incident AIN was 17.5 per 100 person years in the placebo group.  
Quadrivalent HPV vaccine is highly immunogenic in MSM (327) . For those participants  without 
serological or PCR evidence of infection with relevant HPV types at baseline seroconversion rates at 7 
months were 96.5% for HPV-6, 97.4% for HPV-11, 94.1% for HPV-16 rates of and 89.7% for HPV-18.  
4.2.3 Quadrivalent HPV vaccine efficacy - HIV positive 
There is a comprehensive review of HPV vaccination in the recently published BHIVA vaccination 
guidelines (157).  HPV vaccination is considered safe and seroconversion rates are usually greater than 
85%. In some but not all studies, seroconversion rates and antibody titres are highest in those receiving 
ART and those with higher CD4 counts. There is very limited cohort evidence that vaccinating 
individuals with high grade anogenital dysplasia reduces the risk of recurrent dysplasia (328) and that 
such a strategy would be cost-effective or even cost-saving (329). Randomized controlled trials are 
needed.  
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4.2.4 Nonovalent (9-valent) HPV vaccine 
The US Advisory Committee on Vaccination Practices recommended the use of 9-valent HPV vaccine 
for routine vaccination including MSM up to the age of 26 years in March 2015 (330). US providers will 
move from the use of quadrivalent to 9-valent vaccine over the course of 2016. Discussion of 9-valent 
vaccine is not included in the recent JCVI interim statement on vaccination of MSM in the UK (323). 
 
4.2.5 Economic analysis 
In a cost-effectiveness modelling analysis of targeted HPV-vaccination of young MSM in the USA, 
vaccination was considered likely to be cost-effective even when considering vaccination of 26 year 
olds with an assumption of exposure to vaccine HPV types of 50% (331).   In an unpublished UK analysis 
reviewed by the JCVI, vaccinating HIV positive MSM was incrementally cost-effective up to age 40 using 
the list price of qHPV. Vaccination of all MSM  was cost effective at a threshold vaccine price (not 
stated) below list price but was not cost effective at list price (157). 
 
4.2.6 HPV vaccination to reduce risks of HIV transmission 
In a meta-analysis of observational studies prevalent HPV was associated with an approximate 
doubling of risk of HIV acquisition(332). However in the one study within this report performed in MSM 
infection with one HPV type compared with no HPV infection was not significantly associated with HIV 
acquisition (aHR=2.0 (95%CI=0.61-6.5)). However, the presence of infection with 2 or more HPV types 
compared with being HPV un-infected was associated with HIV acquisition (aHR=3.5 (95%CI=1.2-10.6)) 
(333). 
4.2.7 HPV vaccine acceptability  
In a systematic review of HPV vaccine perceptions amongst MSM a wide range of views were reported. 
However more than 50% of individuals were prepared to consider vaccination if offered. Most studies 
were conducted in North America. Further studies in those with little or no sexual experience, who 
would benefit most from HPV vaccination are required (334).   
Recommendations 
 MSM should be encouraged to attend sexual health services for preventative health 
interventions including hepatitis B and HPV vaccination at the time of considering 
commencement of sexual activity (1B) or as early as possible after commencing sexual 
activity (1B). 
 
 All MSM aged 45 years and younger should be offered standard HPV vaccination (0, 2 and 6 
months) irrespective of HPV and HIV status (1B).  
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Partner notification (PN) in MSM  should follow general guidance provided by the Society of Sexual 
Health Advisers (SSHA) (335) and by the British Association for Sexual Health and HIV (BASHH) in 2012 
(275).  A systematic review of partner notification strategies and outcomes concluded that in MSM 
partner notification can reduce disease incidence, condomless sex, sex with infected partners, 
reinfection rates and other adverse outcomes (336, 337). Recognised barriers to PN such as resistance 
affect MSM (338), but other factors including higher partner numbers and sex with anonymous and 
pseudoanonymous partners may present additional challenges. Attitudes to PN vary significantly 
according to partner status and the infection involved (339)  
 
5.2 Anonymous Partners  
 
Partner notification which relies on a case finding approach alone has always had limited effect in MSM 
in whom sexual contacts may be anonymous, contacted through established methods of meeting 
partners including sex-on-premises venues such as saunas or in public sex environments. Where no 
contact details are available, "Hot spotting" is a technique for identifying where the index client met 
their contacts.  Real or virtual venues or sites that are recurrently named as meeting places are 
targeted with health promotion information with the aim of facilitating testing. Although it may not be 
possible to identify a core group or individual in person it may be possible to reduce the ongoing 
transmission of infections through the identification of common venues (340). The delivery of such 




 Information obtained in the course of individual case finding should be combined to identify 
and target locations where STI transmissions are likely to occur (2C) 
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5.3 Pseudoanonymous partners 
 
Use of the internet to find sexual partners is extensive and more commonly reported by MSM than 
other STI clinic attendees (342).  Men who use the internet to meet partners have a greater number of  
partners (343) and a higher probability of being diagnosed with an STI (344, 345) than men recruited in 
community based or national probability samples. Meta-analysis showed that UAI, including UAI with 
serodiscordant partners was more common in men who met partners online (346).  Social media sites 
and more recently Geosocial networking smartphone apps (apps) are widely used in combination with 
pseudonyms, which preclude the use of names, addresses or telephone numbers in tracing contacts.   
A systematic review of new technology in partner notification identified 379 papers published 2000 to 
2012 (347). MSM were the first patient group in whom provider use of the internet for PN was  
reported and much of the published literature applies to MSM. Only one published study compared 
provider PN using the internet to ‘conventional PN’ in an unmatched patient group, finding it to be less 
effective when used instead of conventional methods (348). However as an adjunct to conventional 
methods it increased the number of syphilis contacts tested and treated by 26% (349). Several studies 
show it to be more acceptable to MSM than to the general population (350) and a high proportion of 
English MSM reported that they would engage with a health care worker in an on-line chat room (351). 
Patient initiated PN is supported by the LetThemKnow tool first used in Melbourne (352) and provided 
in the UK by GMFA (353, 354), allowing patients to send a code to contacts via text, website or app. 
 
Smartphone apps have overtaken the internet as the most common method for meeting partners for 
casual sex (355) , but there are as yet no systems that allow direct linkage to these apps in order to 
send messages directly to contacts who need to be notified. The engagement of app providers with 
healthcare organisations is variable and some apps exist with the explicit purpose of facilitating 
condomless anal sex. A large cross sectional study in Los Angeles found that men who used apps to 
meet partners had a higher probability of being diagnosed with chlamydia and gonorrhoea (but not 
syphilis or HIV) than men who met using other methods (356). There is evidence that men who use 
apps have a higher number of partners (both on and offline) than men who meet partners offline 
alone, but do not differ in other demographics or personality variables (357). The app profile 
information often includes no true identity details, so patient referral is the only mode of PN currently 
possible in situations where an app contact has not been followed up by SMS text or internet contact. 
Patient initiated PN using email appears to be more acceptable to MSM than to other patient groups 
but where options are available; communication in person is preferred to the use of email or e-card, or 
to text messaging (358). Patient led referral is preferred for regular and known partners whereas 





 Use of the internet to find partners should be employed as a marker of increased partner 
numbers, bacterial STI risk and risk of UAI with serodiscordant partners (1A) 
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 Provider use of internet partner notification (IPN) or text or app based PN increases the 
number of MSM contacts successfully contacted and should be used as an adjunct to 
conventional methods (1C) 
 
 Patients should be advised of and supported in the use of internet, App or text based PN but 
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Section 6: STI & HIV prevention for MSM 




Combination HIV prevention requires a multi-faceted approach encompassing behavioural, biomedical, 
structural and increased testing interventions, including those delivered in clinical settings (359). Brief 
behaviour change interventions for MSM, including consideration of serosorting and negotiated safety 
for HIV positive MSM are covered in the UK National Guideline on Safer Sex Advice (45).  
 
6.2 Antiretroviral pre-exposure prophylaxis (PrEP) 
 
6.2.1 PrEP Effectiveness 
An overall reduction in HIV transmissions of 44% (95% CI 15-63%) was reported in the iPrEx study, the 
first large randomised placebo controlled efficacy trial of daily oral tenofovir disoproxil fumarate (TDF) 
– emtricitabine (FTC) as PrEP in MSM and transgender women (360).TDF alone has been demonstrated 
to be effective in heterosexual men and women but is not recommended in MSM in CDC or European 
PreP guidelines (due to lack of evidence of effectiveness rather than evidence of no effect) (235). The 
PROUD study, a pilot study of the use of daily oral PrEP (TDF-FTC)), conducted in MSM attending 13 
sexual health clinics in England was subject to early discontinuation of the deferred treatment arm due 
to an unexpectedly high rate of HIV in this group (9 per 100 person years) and an 86% (90%CI 64-96%) 
reduction in HIV seroconversions in men in the immediate treatment arm (361, 362). PROUD inclusion 
criteria were the reporting of condomless anal sex on one or more occasions in the last 90 days and the 
likelihood in the opinion of the participant of further condomless anal sex in the next 90 days. The 
ANRS IPERGAY study of ‘on demand’ use of TDF-FTC PrEP (two tablets 2-24 hours before sex and one 
tablet a day through to two days after the last condomless sex act) also showed an86% reduction in 
HIV seroconversions compared to placebo (363). Adherence to on demand PrEP (defined as reporting 
taking at least 1 tablet before and 1 tablet after sex) was 43%; no tablets before or after were taken in 
28% of sex acts, and suboptimal adherence (one before or one after) was reported in 29% of acts. In 
spite of this, effectiveness was very high, suggesting that participants were able to judge the risk with 
reasonable accuracy. The median monthly dose of tablets of 15 was approximately half of the total 
monthly dose of tablets in the PROUD study. Such a regimen offers obvious potential financial and cost 
benefit implications. Importantly it offers a choice of regimen for MSM whose frequency of risk is 
diverse. 
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The CDC has provided comprehensive guidance on PrEP use (235). A joint BHIVA BASHH position 
statement on PrEP in UK was updated in May 2016 and includes  guidance for clinicians providing  
advice on and monitoring for PrEP including that purchased online (364).  A BASHH/BHIVA UK 
Guideline on PrEP is in preparation. 
Recommendations 
 PrEP with on demand or daily oral tenofovir-emtricitabine (TD-FTC)should be offered to HIV 
negative MSM who are identified as being at elevated risk of HIV acquisition through 
condomless anal sex (1A) 
 
 PrEP with on demand or daily oral TD-FTC should be offered to HIV negative MSM whose 
regular partners are newly diagnosed with HIV infection, until the partner’s serum viral load 
reaches undetectable levels (1C ) 
 
 TD alone should not currently be offered as PrEP to MSM (2C) 
 
6.2.2 PrEP adverse effects 
Adverse effects are an uncommon cause of discontinuing PrEP (365). Gastrointestinal effects were 
reported in <10% of those receiving TDF-FTC as PrEP in iPrEx, were mild and resolved within 1 month of 
initiating therapy (360). Proximal renal tubular dysfunction and measurable loss in bone mineral 
density have been reported with therapeutic tenofovir (TDF) use. A 1% reduction in bone mineral 
density was observed when TDF was used as PrEP but has not been associated with increased fracture 
rate and no increase in renal complications was reported (366). Viral resistance to either tenofovir DF 
or emtricitabine was rare and almost all cases were thought to be infected at or immediately after 
enrolment in the study (360, 361). A modelling study of the UK epidemic suggested resistance would 
have a negligible impact on PrEP efficacy at a population level (367). Baseline HIV testing using 4th 
generation serological testing, supported by a point of care test if indicated, should always be 
undertaken on commencing PrEP, but a history of condomless sex within the HIV window period was 
not an exclusion criterion in the PROUD study. Starting PrEP should be avoided in men with current 
symptoms suggestive of HIV seroconversion until infection can be reliably excluded. There was no 
evidence of risk compensation with the use of PrEP in iPrEx , but this was a placebo-controlled study 
(368). In the PROUD study, after adjustment for the number of STI screens, there was no difference in 
the rate of bacterial STI between the immediate and deferred groups and the rate of rectal infections 
was the same (RR 1.00) in both groups. However, a greater proportion of the immediate group 
reported receptive anal sex without a condom with ten or more partners at 1 year compared to the 
deferred group (21% vs 12%, p=0.03)  (361). In the open label phase of the IPERGAY study  there was a 
decrease in overall reported condom use over time (P=0.0003)(369) and a large observational cohort 
of MSM on PrEP reported that condom use declined in 41% of those on PREP (370) . There is therefore 
some evidence of risk compensation among MSM taking PrEP ; however, longer term real-world data is 
lacking. Repeat HIV testing and tests for other STIs should be offered every 3 months (235, 364). Serum 
creatinine and estimated Glomerular Filtration Rate (eGFR) should be checked every 3-6 months and 
Hepatitis C serology at least once a year. Routine urinalysis for proteinuria with urinary 
protein:creatinine ratio and albumin:creatinine ratio if there is more than a trace of protein is 
recommended by some authorities. Provision of behavioural interventions alongside routine 
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monitoring may be indicated in reducing the frequency and/or duration of PrEP use but there is 







 PrEP can be commenced while waiting for the results of baseline HIV testing (1A) unless 
there are symptoms suggestive of HIV seroconversion (1C)  
 




 PrEP should be offered as part of a package of care including regular (3 monthly) HIV and STI 
testing and monitoring of renal function (1C) 
 
 MSM should be informed about the potential side effects of PrEP medication  (1D) 
 
 MSM receiving PrEP should receive advice on the high risk of other STIs and the need for 
regular testing  (1B) 
 




6.2.3 Awareness and availability of PrEP 
Awareness of and willingness to use PrEP is higher in MSM than in other groups, most studies having 
been conducted in the US (371). Community based surveys in London (372) and Scotland (373) have 
assessed awareness and willingness to use PrEP among UK MSM. In both studies around half of men 
questioned would consider PrEP use and reporting condomless anal sex was associated with a higher 
likelihood of considering PrEP. An on-line study of MSM from Scotland, Wales and Northern Ireland 
who reported condomless anal sex with ≥2 men in the last year showed 34.5% of participants were 
aware of PrEP but 58.5% reported that they would be willing to use PrEP if it were available to them 
(374).  
A qualitative study of focus groups including MSM revealed concerns about adherence, condom non- 
use and other STIs (375). Use of PrEP following inclusion in randomised controlled trials is higher in 
older and more educated men (365), suggesting that additional information and publicity about PrEP is 
required to ensure equity of access. Cost effectiveness of PrEP is highly dependent upon HIV incidence 
rates and the price of drug (376-378). Targeting MSM in serodiscordant relationships (in the absence of 
treatment) is most cost effective but has negligible effect on HIV incidence and less relevant as early 
treatment becomes the norm (376, 379). UK cost effectiveness studies give a wide range of possible 
outcomes in sensitivity analyses showing that PrEP cost effectiveness in MSM is highly dependent upon 
uptake, duration of use, drug costs, real-life effectiveness and changes in HIV test uptake and condom 
use resulting from PrEP availability.  Identification of subgroups of MSM with the highest HIV incidence, 
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managing the duration of PrEP use and the use of event-based PrEP and obtaining antiretrovirals  at a 
reduced price on the patent expiry of Truvada in 2018 will be critical to ensuring cost-effective 
implementation (380, 381). 
 
PrEP access in NHS England is planned  through a large scale clinical trial (IMPACT) enrolling 10,000 
participants over 3 years(382). The European Medicines Agency recommended that Truvada was 
granted a marketing authorisation in Europe for PrEP in July 2016. In Scotland, a marketing license for 
PrEP was granted by the Scottish Medicines Consortium  in April 2017, allowing PrEP to be made 
available through NHS clinics from July 2017.  Where PrEP is indicated but not accessible through the 
NHS in the UK, MSM have accessed medication through private medical clinics or online. Purchase of 
PrEP online is increasingly routine (383, 384). Guidance for individuals who wish to pursue this route is 
available and the GMC has provided advice for UK clinicians wishing to support monitoring (including 
therapeutic blood monitoring) for those using this route. Generic versions of Truvada  can be legally 
imported to the UK for personal use (383). Guidance for patients on importing ART for personal use 
and on MRHA regulations is available online (385). Clinicians should clarify local arrangements for 
provision of advice and monitoring for non-NHS supplied medications.  MSM obtaining PrEP either 
through NHS provision or personal  import should be provided with detailed guidance on the on-
demand use of PrEP where appropriate (364) and recommended  tests including baseline 4th 




 MSM at risk of HIV infection should be made aware of the availability of PrEP through all 
services proving sexual health care (1C) 
 
 If PrEP is not available to men at risk who are willing and able to pay for it, they should be 
directed to  guidance on reputable sources of medication (1D) 
 
 PrEP provision should include condom provision and behavioural support (1D) 
 
 
6.3 Antiretroviral post-exposure prophylaxis for sexual exposure 
(PEPSE) 
 
A BASHH/BHIVA guideline  on post exposure prophylaxis (PEP) following sexual exposure to HIV 
(PEPSE) was updated in 2015 (386). PEPSE provision is not recommended in cases where the index 
individual is HIV positive with a viral load of <200copies/ml, regardless of the type of sexual exposure. 
Convenience samples of HIV negative MSM found that 34% of MSM in Spain and 36% in the USA were 
aware of PEPSE availability; having a higher number of sex partners was significantly associated (OR 
5.1, p=0.02) with higher rates of awareness (387, 388). Awareness was higher (52-66%) in MSM living 
with HIV (389, 390). Men who accessed PEPSE in Los Angeles were found to have greater odds of 
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having had gonorrhoea or to have used methamphetamine or inhaled nitrites in the previous year than 
other men who were ‘high risk’, but there was no difference by race or ethnicity (391). Analysis of an 
Australian database of PEP prescribing found that repeat presentation for PEPSE occurred in 17.5% of 
users and that 1.2% of individuals were HIV positive at baseline (392). Higher lifetime and recent sexual 
risk behaviour was associated with lower adherence to PEPSE in a small study of high risk, 
methamphetamine using MSM (393). An increased HIV incidence of 6.4 per 100 person/yrs  among 
MSM prescribed PEPSE verses v 1.6 in a control group was found in an Amsterdam cohort of MSM 
(394) and was higher in PEPSE users than other MSM in an Australian data linkage study (395). A UK 
study comparing 8,801 MSM receiving PEPSE between 2011-2013 with 141,151 who did not, found an 
adjusted HR of subsequently receiving a positive HIV diagnosis in the same service of 1.19 (1.04-1.37) 
(396)  suggesting that PEPSE use is a marker of elevated risk. PEP prescribing outside the  parameters 
defined in UK guidelines is relatively common and is unrelated to prescriber’s grade, setting or 
experience (397). Emergency departments need education, training (398) and protocols to increase 




 PEPSE should be provided through sexual health and out-of-hours services and availability 
publicised to MSM (1C) 
 
 Education of emergency department staff and local protocols are required to ensure 
appropriate advice, baseline HIV testing and follow up for MSM who present requesting 
PEPSE (1C) 
 
 MSM who present for PEPSE constitute a high risk population and should be offered 
additional prevention interventions including frequent HIV and STI testing and PrEP (1B) 
 
 
6.4 Sexual Health of HIV positive MSM  
The sexual health needs of MSM living with HIV should be addressed at diagnosis and as part of routine 
holistic HIV care and monitoring (400). Guidance on sexual and reproductive health of people living 
with HIV (2008) (401) (currently undergoing revision), the management of STIs in people living with HIV 
(2006) (402) and on Safer Sex advice (2012) (45) are directly applicable to MSM living with HIV, but do 
not incorporate recent significant developments relating to the reduction in risk of sexual transmission. 
Following a diagnosis of HIV, highly significant reductions in partner numbers were observed in the first 
12 months in a cohort of 193 MSM (403). There is evidence that among MSM the number of episodes 
on UAI with partners of unknown status and the age-adjusted number of sexual partners do not 
increase up to 5 years after diagnosis (404). A UK study using phylogenetic analysis and clinical data 
found that HIV transmission was strongly associated with younger age, recently acquired HIV infection, 
being ART naive or having concomitant STI. The majority of new infections appeared to be acquired 
from men who had not yet been diagnosed with HIV (405). Mathematical modelling suggests that the 
proportion of new infections attributable to transmission from undiagnosed men is 82% (184). The 
contribution of MSM on effective treatment to onward HIV transmission is likely to be small. However, 
the population rate of acute bacterial STI is up to four times higher in HIV infected compared to HIV 
uninfected or undiagnosed men and this ratio appears to have increased over recent years (406).  
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Particular attention is required to interventions to reduce transmission risk in MSM the first year 
following HIV diagnosis, particularly those have yet to commence or have recently commenced ART, 
and to addressing rates of bacterial STI in men on effective ART. 
6.4.1 Advice on HIV transmission risk 
Advice on HIV sexual transmission risk through oral and anal sex may be required by MSM living with 
HIV and their partners. Clinical trial HPTN 052 trial found that initiating ART in HIV positive individuals 
regardless of CD4 level in heterosexual serodiscordant relationships reduced HIV transmission by 96% 
(407). Only 2% of couples in the trial were MSM. A comparable reduction in transmission risk 
attributable to ART was reported in a small longitudinal clinic based study of 859 MSM in whom a likely 
transmitter was identified by phylogenetic analysis in 41 cases (405). Interim findings from the 
PARTNER study updated in July 2016 (98, 408) included 22000 occasions of anal sex in 340 gay MSM 
couples. The upper 95% confidence limit for the risk of transmission per year through anal sex with a 
partner with undetectable serum HIV viral load was 0.89% (2.7% in the subgroup reporting receptive 
anal sex with ejaculation) due to the low number of person years accumulated. However, no 
phylogenetically linked transmissions occurred despite 16% of MSM acquiring other STIs during follow 
up and the lower 95% confidence interval for the risk of transmission was zero. The investigators’ best 
estimate for the risk of transmission was zero. 34% of men reported condomless sex with other 
partners, underlining the potential risk of both other STIs and of HIV acquisition from non-primary 
partners. A systematic review of studies of oral HIV transmission risk in cohorts including untreated 
individuals reported a non-zero upper confidence limit based on limited data (409) but biological data 
(410) and longitudinal studies support the contention that the risk is significantly lower than that for 
vaginal or anal sex and may be zero in some untreated individuals (45). There is no published estimate 
for an upper confidence limit for transmission risk through oral sex with undetectable HIV viral load but 
given that sexual behaviours in both HPTN 052 and the PARTNER study would include oral sex in both 
heterosexual and MSM couples, it seems that a best estimate of transmission risk for oral sex with 
undetectable viral load is zero. It also follows that this estimate can be made with greater confidence 
than for vaginal or anal sex. BHIVA Treatment Guidelines recommend that the benefits of starting 
treatment to reduce transmission (TasP) should be discussed with all HIV positive patients at diagnosis 
and treatment initiated if the patient wishes (411). Modelling suggests that starting ART at diagnosis is 
both cost effective and cost saving in MSM in the UK (412). NHS England has published a Clinical 
Commissioning Policy on Treatment as Prevention (413). 
 
Recommendations 
 MSM in the first year following HIV diagnosis should be offered additional psychological 
support to address HIV and STI risk behaviours (1B) 
 Younger men living with HIV may require particular attention (2B) 
 The risk of HIV transmission through receptive oral sex with a partner with high serum viral 
load (such as in acute seroconversion) is unknown, but is thought to be non-zero. MSM 
should be advised that oral sex carries an onward transmission risk in this situation (1D) 
 MSM should be advised that the risk of HIV transmission through oral sex with undetectable 
viral load is highly likely to be zero (1B)  
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 MSM should be advised that the risk of HIV transmission through insertive or receptive anal 
sex with undetectable viral load and in the absence of other STIs is low and may be zero. The 
upper estimate of the risk of unprotected receptive anal sex with an HIV positive partner 
with undetectable HIV viral load may be as high as 2.7% per year. This upper estimate may 
fall as further evidence accumulates (1B) 
 All HIV positive MSM including those newly diagnosed with HIV should be offered Treatment 
as Prevention (1B) 
 
6.4.2 STI testing for HIV positive MSM 
Of MSM newly diagnosed with HIV in England in 2013, 25% had a concurrent STI and in that year MSM 
with diagnosed HIV infection accounted for 40% of all new syphilis diagnoses (13). In 2008-9, 6.7% of 
MSM had an incident STI in the year after diagnosis (excluding those at baseline), the rate being 18.8% 
in MSM aged 16-19 years (414). Routine testing of cohorts of MSM in HIV clinics reveals high rates of 
asymptomatic STIs (101, 415-418) and a systematic review found a point prevalence in all HIV infected 
individuals of 16% (97). Opt-out self-screening is effective and acceptable (34) and the detected 
incidence of STIs in MSM was doubled when testing was supported by prompts in the electronic 
patient record (419). BASHH/BHIVA/FSRH sexual health in HIV guidelines recommend at least an 
annual offer of STI screening (401) and BHIVA monitoring guideline recommends 3-6 monthly syphilis 
testing to increase detection of asymptomatic infections (400), consistent with BASHH guidance for all 
MSM (76). Regular serological testing for syphilis can increase the detection of asymptomatic 
infections (420). Cost effectiveness analysis suggests that three monthly syphilis testing is cost effective 
in HIV infected MSM (226) Hepatitis C infection is more common in HIV infected MSM (421, 422) and 
annual antibody testing is recommended, with more frequent testing for those with specific risk factors 
(see 2.1.5). Bacterial STIs are common in MSM screened as part of routine HIV care (416) but partner 
notification procedures may be incomplete in HIV clinics. Having an STI at baseline is an independent 
predictor of incident STI in HIV infected MSM (423) and a risk score developed from observational data 
on a 2129PY of follow up in a large cohort of HIV infected MSM identified prior STI, UAI with other HIV 
infected men, >10 partners and methamphetamine use as predictors of asymptomatic bacterial STI 
(424). Similar predictors have been identified in other cohorts (425). These predictors closely parallel 
predictors in HIV negative MSM (Section 1.5) but identification requires regular sexual history taking 
which is not always reliably performed (426). Inclusion of sexual risk assessment and history taking in 
an HIV care Integrated Care Pathway (ICP) can improve recording (427). A small study of the use of 
prophylactic doxycycline in HIV positive MSM with a history of two or more episodes of syphilis 
showed a highly significant reduction in new diagnoses of bacterial STI despite lower levels of condom 
use (428) but this is not routine practice in the UK. 
Recommendations 
 Syphilis serology should be performed at least annually as part of routine monitoring in 
sexually active HIV infected MSM (1B) 
 A sexual history should be documented at least annually in the routine care of HIV infected 
MSM (1C) 
 MSM under the age of 20 years and those with risk factors including prior STI, UAI with other 
HIV infected MSM, recreational drug use associated with sex, Chemsex, >10 partners should 
be offered opt-out STI screening at every HIV care visit and/or at 3 monthly intervals (2B) 
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7 Sexual Problems and Dysfunctions in 
MSM 
 
Dr Stuart Gibson 
7.1 Introduction 
 
Sexual problems and dysfunctions affecting MSM can have significant adverse effects on quality of life 
and have been associated with a self-reported history of sexually transmitted infections in a large cross 
sectional internet survey sample (429).  It has also been argued that they can contribute to sexual risk 
taking (430-432). In addition to individual interventions, suggested population interventions have 
included greater clarity on the criminalisation of HIV transmission and efforts to reduce HIV-related 
stigma (433). 
 
7.2 Clinical Features and Aetiology 
 
Problems including low sexual desire, erectile dysfunction and ejaculatory dysregulation have been 
reported in large samples of MSM across the UK, US, Australia and Europe (429-431, 433-436). Distress 
associated with anodyspareunia (pain with receptive anal penetration) has also been reported as 
having a negative impact on sexual pleasure and activity (436). Sexual problems are associated with 
depression, performance anxiety, low self-confidence and poor self-image (429, 431, 433, 437) and 
there are complex interactions between depression, anxiety, general wellbeing, sexual risk taking and 
HIV infection (431, 432). Recreational drug use and problematic alcohol use have also been identified 
as risk factors for sexual dysfunction (429, 437). 
 
MSM living with HIV report greater numbers of sexual problems and dysfunctions compared to MSM 
who are HIV negative (431, 435, 436, 438). This has been related to psychological factors (432) and to 
duration of antiretroviral therapy, but no association has been found with any specific class of 
antiretrovirals (439). Sexual problems such as erectile dysfunction have also been associated with using 
sex as an avoidant strategy to cope with daily life stress and sexual risk taking in casual encounters 
(430). Both delayed ejaculation and erectile difficulties have also been associated with antidepressant 
SSRIs in HIV-positive MSM (432). 
 
MSM Guideline Final Accepted version 021117. Note this version does not include typesetting and 




Men may present with symptoms of sexual dysfunction as the primary concern. However, questions 
relating to sexual dysfunction should be part of the routine assessment of men reporting high risk 
sexual behaviour. Particular attention should be paid to men living with HIV and those reporting 
problematic alcohol or recreational drug use. Identifying whether the problem is primary or secondary 




 Assessment of sexual risk behaviour in MSM should include routine inquiry into sexual 




To date, evidence based reviews and treatment guidelines for psychological interventions with male 
sexual difficulties have been based on heterosexual men. It has been argued that the models used to 
conceptualise and treat sexual problems such as ED or PE are based on the heterosexual experience, 
with little acknowledgement of how it could be different for MSM (440). Such issues are likely to apply 
to the assessment of suitability for, but not the prescribing of, pharmaceutical therapies. 
 
There is also a general lack of evidence to guide a more holistic sense of sexual wellbeing in MSM. An 
analysis of nearly 13,000 UK responses from the 2010 European Men-who-have-sex-with men Internet 
Survey to a general question on what constitutes the ‘best sex’ (441) found that the most commonly 
identified theme was a desire for sex within committed relationships, followed by a desire for sex that 
is emotionally or psychologically connected.  
 
A recent systematic review   (442) concluded that psychological therapies improved sexual functioning 
but it was recognised that the methodological quality of many of the studies was limited.  International 
Society for Sexual Medicine (ISSM) evidence-based guidelines for psychological interventions men who 
have ED and PE concluded that the psychological literature has made an important contribution to the 
description, aetiology, and diagnosis of these difficulties but there is a lack of large, randomized, and 
controlled studies demonstrating the efficacy of such interventions (443). Interventions for ED included 
psychodynamic interpretations of anxiety, systematic desensitization, sensate focus, couples therapy, 
behavioural experiments, psychosexual education, communication skills training, and masturbation 
exercises. Overall, it is not clear which of these interventions in combination or alone has the greatest 
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efficacy but the evidence clearly indicates that these interventions help men to improve their 
relationship and sexual life (443).  
 
For PE, psychological interventions range from psychodynamic to systemic, behavioural, and cognitive 
approaches. Besides teaching self-control techniques to delay ejaculation, psychological interventions 
aim to reduce performance anxiety, improve communication with sexual partners and resolve issues 
that precipitate and maintain the sexual problem. Psychological interventions for PE are generally 
effective but the evidence base for such interventions is not considered to be as clear or reliable as the 
findings from the research on ED (444) . Combining pharmacological and psychological treatments can 
be especially useful in men with acquired premature ejaculation where there is a clear psychosocial 
precipitant or lifelong cases where the individual or couple’s responses to PE are likely to interfere in 
the medical treatment and ultimate success of therapy (445). NICE has recently issued guidance on the 
use of dapoxetine in the first line treatment of PE (446).  For men with PE and comorbid ED, 
combination therapy may also be helpful to manage the psychosocial aspects of these sexual 
dysfunctions (444). 
 
The existing guidelines for treating men who have sexual dysfunctions such as ED and PE (443, 444, 
447), including men who are HIV-positive (401), are applicable to working with MSM.  However, none 




 Psychosexual counselling, behavioural interventions, pharmaceutical and/or psychological 
therapy should be offered to MSM as part of treatment for sexual dysfunctions such as low 
sexual desire, erectile difficulties or ejaculatory dysregulation (1C) 
 
 Interventions should be relevant and appropriate to the sexual identities, sexual practices 
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 Proportion of services offering STI testing for MSM that include NAAT testing for NG and 
CT from throat, urine and rectum, HIV, syphilis, hepatitis B and where indicated hepatitis C 
serology. Target 100% 
 Proportion of services offering opt- out testing for HIV infection to all MSM. Target 100% 
MSM Guideline Final Accepted version 021117. Note this version does not include typesetting and 







 Proportion of MSM in whom a history of alcohol and recreational drug use, 
including injecting drug use is recorded. Target 97% 
 Proportion of MSM in whom risk factors for Hepatitis C are recorded (including 
traumatic anal sex, fisting, shared sex toys, group sex, sero-sorting and concomitant use of 
recreational drugs). Target 97% 
 Proportion of men with identified risk factors for Hepatitis C in whom the offer of 






 Proportion of MSM STI screens which include a test for syphilis. Target 97% 
 
 Proportion of MSM screens including an HIV test, after excluding known HIV 
positive individuals. Target 87%  
 
 
Recall and testing frequency 
 
 
 Proportion of MSM with rectal bacterial STI diagnosed who are recalled for H I V  
testing at 3 months: Target 97%  
 Proportion of MSM retested for HIV infection within 4 months of attendance for 
treatment for syphilis, gonorrhoea or rectal or urethral chlamydial infection. Target 50%  
 
Sexually Transmitted Enteric Infections 
 
 
 Proportion of cases rectal chlamydia in HIV positive MSM typed for LGV serovars. 
Target 97% 
 
 Proportion of symptomatic men with proctitis in whom rectal chlamydia status is 
unknown who are treated with recommended LGV treatment. Target 97% 
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 Proportion of men reporting condomless anal sex with more than one partner in the 
last 3 months advised on the availability of PrEP with daily or event based (on demand) oral 
Tenofovir/emtricitabine. Target 97% 
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Appendix 1. Search terms: 
Section 1: 
MSM AND Access to care, Outreach, generic, Service, Primary Care. MSM OR Gay AND Proctoscopy, 
Sexual History, Examination, Hepatitis  
 
Section 2.1 




Men who have sex with men OR MSM OR gay men AND HIV, HIV seroconversion, acute 
seroconversion, HIV testing, HIV AND Home sampling, HIV AND home testing, MSM AND couples 
AND HIV testing 
 
Section 3 
PubMed Search up to December 2014 using MeSH terms: 
((((("colitis"[MeSH Major Topic] OR "enterocolitis"[MeSH Major Topic]) OR "proctocolitis"[MeSH 
Major Topic]) OR "proctitis"[MeSH Major Topic]) OR "gastroenteritis"[MeSH Major Topic])) AND 
(((gay[MeSH Major Topic]) OR homosexual[MeSH Major Topic]) OR MSM[MeSH Major Topic]) 
 ((((((((dysentry[Title/Abstract]) OR diarrhoea[Title/Abstract]) OR shigella[Title/Abstract]) OR 
ETEC[Title/Abstract]) OR EHEC[Title/Abstract]) OR vero[Title/Abstract]) OR VTEC[Title/Abstract])) 
AND (((MSM[Title/Abstract]) OR gay[Title/Abstract]) OR sexual[Title/Abstract]) 
 ((((("colitis"[MeSH Major Topic] OR "enterocolitis"[MeSH Major Topic]) OR "proctocolitis"[MeSH 
Major Topic]) OR "proctitis"[MeSH Major Topic]) OR "gastroenteritis"[MeSH Major Topic])) AND 
“Disease transmission, infectious”[MeSH Major Topic] 
 ((((("colitis"[MeSH Major Topic] OR "enterocolitis"[MeSH Major Topic]) OR "proctocolitis"[MeSH 
Major Topic]) OR "proctitis"[MeSH Major Topic]) OR "gastroenteritis"[MeSH Major Topic])) AND 
“Therapeutics”[MeSH Major Topic] 
 ((((("colitis"[MeSH Major Topic] OR "enterocolitis"[MeSH Major Topic]) OR "proctocolitis"[MeSH 
Major Topic]) OR "proctitis"[MeSH Major Topic]) OR "gastroenteritis"[MeSH Major Topic])) AND 
“Diagnosis”[MeSH Major Topic] 
 
 
i. 2013 European Guideline on the management of proctitis, proctocolitis and enteritis caused 
by sexually transmissible pathogens  
ii. Sexually Transmitted Diseases Treatment Guidelines, 2010. Centers for Disease Control and 
Prevention 
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iii. Clinical Knowledge Summaries, National Institute for Health and Care Excellence 
(http://cks.nice.org.uk/) 








MSM AND Partner Notification, Apps, Online 
 
Section 6 
Men who have sex with men OR MSM OR gay men AND HIV, HIV seroconversion, acute 
seroconversion, PEP, PrEP, HIV prevention, MSM or Men who have sex with men AND HIV 
infected AND STI 
 
Section 7  
MSM AND sexual, psychosexual, difficulties, premature ejaculation, erectile dysfunction, (low) sexual 
desire, sexual compulsion  
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Appendix 2: Additional Information on 
symptomatic gastrointestinal 
infections. 
Appendix 2.1: Map  
 
 







Appendix 2.2: Assessment of severity of dehydration 
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Appendix 2.3: Guidance on collecting a faecal specimen for 
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Appendix 2.4: Advice on preventing spread of infection (285)  
 
 Hands should be washed thoroughly with (preferably liquid) soap in warm running water 
and dried after going to the toilet and before preparing or serving food or eating meals. 
 Towels and flannels should not be shared. 
 A flush toilet should be used if possible. If a commode or bedpan must be used, it should be 
handled with gloves, the contents disposed of into the toilet, and the container then washed 
with hot water and detergent and allowed to dry. 
 Soiled clothing and bed linen should be washed separately from other clothes and at the 
highest temperature they will tolerate (for example 60°C or higher for linen), after removal 
of excess faecal matter into the toilet. Soaking in disinfectant is not necessary. The washing 
machine should not be more than half full to allow for adequate washing and rinsing. 
 Toilet seats, flush handles, basin taps, surfaces, and toilet door handles should be cleaned at 
least once daily with hot water and detergent. A disinfectant (if available) and a disposable 
cloth (or one dedicated for toilet use) should be used to clean toilets. 
 They should not go to work or other institutional settings until at least 48 hours after 
diarrhoea has stopped. Public health authorities will advise if a pathogen is isolated from the 
person's stool sample: longer periods of exclusion are required in some circumstances. 
 They should avoid entering swimming pools for 2 weeks after the last episode of diarrhoea. 
 
 
